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Acute graft-versus-host disease (aGvHD) is a severe complication that frequently occurs 
after allogeneic hematopoietic stem cell transplantation and results in a high transplant-
related morbidity and mortality. Glucocorticoids (GCs) are widely used to treat aGvHD 
but some patients are refractory to this therapy. Importantly, the mechanisms of GC-
resistance remain partially unclear. In our study, we used an aGvHD mouse model based 
on the transplantation of allogeneic GC-resistant donor T cells derived from cell type-
specific GC receptor (GR) knock-out mice. We found that mice transferred with GC-
resistant T cells developed a more severe aGvHD than those receiving GC-responsive T 
cells. We then analyzed the expression of 54 candidate genes in the first full-blown phase 
of the disease in the inflamed small intestine, an organ that is strongly affected by 
aGvHD, by using a high-throughput gene chip technology, and found that the majority of 
genes were significantly up-regulated in mice transplanted with GC-resistant T cells. In 
addition, we performed RNA-sequencing to identify further GC target genes in the small 
intestine, and confirmed differential expression of 26 of them by using high-throughput 
quantitative RT-PCR. Our findings revealed an altered gene expression profile caused by 
GC-resistance of transplanted allogeneic T cells in aGvHD, which might be helpful to 
derive biomarkers or develop new therapeutic concepts. Since GCs not only improve 
aGvHD but also compromise the beneficial graft-versus-lymphoma (GvL) reaction of the 
allogenic donor T cells, we also explored whether a specific delivery of GCs may retain 
the GvL activity but still suppress aGvHD. In our study, we used a nanosized formulation 
of GCs (BMP-NPs), which are encapsulated in inorganic-organic hybrid nanoparticles 
that are preferentially taken up by macrophages, to treat mice in a combined aGvHD/GvL 
mouse model. By detecting the abundance of Bcl1 lymphoma cells in the blood, we found 
that treatment with BMP-NPs delayed the development of an adoptively transferred 
lymphoma better than free GCs in our disease model, suggesting that BMP-BPs reduce 
aGvHD in mice and partially retain the GvL effect. Collectively, this work provides new 
insights into how treatment of aGvHD, in particular with GCs, could be improved in the 
future. 
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1. Introduction  
1.1 Hematopoietic stem cell transplantation 
Hematopoietic stem cell transplantation (HSCT) is one of the most effective therapeutic 
approaches to treat many blood-related malignancies (Appelbaum F.R., 2001; Copelan, 
2006) and as well as to various non-hematological diseases, such as solid tumors 
(Ljungman et al., 2010) and severe autoimmune disorders (Sykes and Nikolic, 2005). In 
1957, more than 60 years ago, Thomas and his co-workers attempted and successfully 
conducted the intravenous infusion of bone marrow from healthy donors to treat patients 
with aplastic anemia or hematologic neoplasia after irradiating them (Thomas et al., 
1957). Due to his contributions to the clinical use of HSCT, Thomas was awarded the 
Nobel Prize in Medicine in 1990 (Boieri et al., 2016). Ever since then, HSCT has been 
widely used in clinical practice. Bone marrow is the richest source of hematopoietic stem 
cells. Others include peripheral blood (PB) and umbilical cord blood (UCB). HSCT of 
infused cells from peripheral blood was performed in dogs in 1979 (Korbling et al., 1979) 
and using  UCB as the cellular source in HSCT was first reported in 1995 (Wagner et al., 
1995). HSCT can be subdivided into three groups based on the origin of the transplanted 
cells: 1) allogeneic HSCT, transplanted cells are from an unrelated donor, optimally a 
fully HLA-matched individual; 2) syngeneic HSCT, transplanted cells are from a 
monozygotic twin; and 3) autologous HSCT, transplanted cells are obtained from the 
patients themselves (Saccardi and Gualandi, 2008). Based on data from the Center for 
International Blood & Marrow Transplant Research (CIBMTR), over 23,000 patients in 
the US underwent an HSCT in 2018 (8,500 receiving an allogeneic HSCT and 14,500 
receiving an autologous HSCT) (D’Souza and Fretham, 2018). Before being treated with 
a hematopoietic stem cell infusion, patients with a lymphoma or leukemia are commonly 
given conditioning regimens which aim to decrease tumor burden and to eradicate the 
host immune system to prevent graft rejection (Gyurkocza and Sandmaier, 2014). High-
dose myeloablative condition regimens are administered to patients with hematologic 
malignancies, such as a high-dose total body irradiation (TBI) or high-dose chemotherapy. 
Treatment with a TBI is often combined with the administration of immuno-suppressive 





conditioning regimens reduce the relapse rate of the patients, they also cause some 
gastrointestinal, pulmonary and hepatic toxicity and a loss of the patients’ hematopoietic 
system, and are not appropriate to treat elder patients (Jenq and van den Brink, 2010). 
Therefore, non-myeloablative conditioning or reduced intensity conditioning (RIC) 
regimens have been developed. Many clinical studies have indicated that the rates of 
relapse are less in patients undergoing an allogeneic HSCT (allo-HSCT) than those ones 
transplanted with syngeneic or autologous grafts (Weiden et al., 1979).  In the setting of 
allo-HSCT, it has been shown that allogeneic grafts are capable of eradicating malignant 
cells of the patients through its graft-versus-tumor (GvT) effect. This discovery has led to 
the development of non-myeloablative conditioning regimens that are accessible for elder 
patients who fail not tolerate high-dose TBI or other myeloablative regimens (Gyurkocza 
and Sandmaier, 2014; Singh and McGuirk, 2016). Diverse non-myeloablative regimens 
have been developed by many research centers: Fred Hutchinson Cancer Research Center 
performs a low dose, 2 Gy TBI-based regimen (McSweeney et al., 2001), and the MD 
Anderson Cancer Center developed a regimen of peritransplant rituximab combined with 
fludarabine (90 mg/m2) and cyclophosphamide (2250 mg/m2) to treat patients with a 
relapsed follicular lymphoma (Khouri et al., 2008).   
 
1.2 Graft-versus-Host Disease and Graft-versus-Tumor effects 
1.2.1 Graft-versus-Host Disease 
Allogeneic HSCT is an effective treatment for the majority of patients suffering from 
hematological malignancies and is considered to be the only curative approach to treat 
the patients with aggressive T-cell lymphoma/leukemia (ATL) (Utsunomiya, 2019). 
However, it is accompanied by the risk of developing Graft-versus-Host Disease (GvHD), 
which is responsible for the high transplant-related morbidity and mortality of these 
patients (Holtan et al., 2014). According to the report from CIBMTR, GvHD accounts for 
11% and 12% of deaths, respectively, that occurred within 100 days or beyond 100 days 
after allogeneic HSCT in 2015-2016 (Souza A et al., 2018). The human leukocyte antigen 





crucial role in the development of GvHD. There are more than 200 genes located in this 
region on human chromosome 6 that span more than 4 megabases. However, in the 
context of allo-HSCT, the three genes HLA-A, HLA-B, and HLA-C play the most 
important role, forming the HLA barrier to successful HSCT. It is well-known that acute 
GvHD is mainly driven by donor T cells contained in the graft (Perkey and Maillard, 
2018). Namely, CD4+ T cells recognize antigens presented by HLA class II molecules 
and antigens presented by HLA class I molecules are preferentially recognized by CD8+ 
T cells. Donor T cells recognize host cells as foreigners and attack them, leading to tissue 
damage which is one of the main features of GvHD. T cell-depleted (TCD) grafts have 
been infused into the host to avoid the development of GvHD (Collins and Fernández, 
1994). Although many clinical studies showed that TCD grafts significantly reduced the 
occurrence and severity of GvHD, it is associated with severe life-threatening infections 
and increased tumor relapse rates. Besides, the fatal infections are caused by the lack of T 
cell-mediated immunity against viral antigens, whereas, the high rates of relapse 
strengthen the importance of donor T cells in eliminating malignant tumor cells after 
conditioning.  
GvHD comes in two distinct forms: acute GvHD (aGvHD) and chronic GvHD (cGvHD). 
Historically, aGvHD was defined as clinical symptoms arising within 100 days after 
HSCT, whereas a disease developing later was referred to as cGvHD. More recently, it 
was noted that both forms differ in pathogenesis, clinical manifestations and organ 
involvement, criteria henceforth forming the basis for the classification of both types of 
GvHD (Boieri et al., 2016). Development of aGvHD is responsible for up to 15% deaths 
of the patients and more than 50% of allo-HSCT patients develop aGvHD. The organs 
affected by aGvHD include the skin (81% of patients with aGvHD), liver (50%) and 
gastrointestinal tract (54%) (Martin et al., 1991).  Based on the severity of the damage 
caused to the involved target organs (skin, liver, and gastrointestinal tract) and clinical 
performance, aGvHD has been divided into four grades (grade I - IV) based on the 
criteria established by Glucksberg and the International Bone Marrow Transplant 
Registry Systems (Glucksberg et al., 1974; Rowlings et al., 1997).  Grade I aGvHD is 





undergoing HSCT, 30 - 50% develop aGvHD of grade I/II, and approximately 14% have 
severe aGvHD of grade III/ IV (Zeiser and Blazar, 2017). 
 
1.2.2 Graft-versus-Tumor Effects 
Allogeneic donor T cells are thought to be the main cause of aGvHD after allogeneic 
HSCT. On the other hand, they contribute to a beneficial impact on eradicating malignant 
cells in the recipients referred to as Graft versus Tumor effects (GvT) or Graft-versus-
Lymphoma (GvL) effect (Negrin, 2015). The GvT effect was first discovered by Barnes 
et al. performing allogeneic HSCT in murine studies in 1956. It showed that the leukemia 
was eliminated in mice receiving allogeneic HSCT compared to those receiving 
syngeneic HSCT, and mice transplanted with allogeneic cells developed some syndrome 
of diarrhea which has been recognized as one of the manifestations of GvHD today 
(Barnes et al., 1956). Subsequent studies indicated that the disease relapse rate was lower 
in patients suffering from aGvHD or cGvHD, and that the GvT effect existed in the 
patients undergoing allo-HSCT without the incidence of GvHD, suggesting that GvHD 
and GvT effect can occur independently (Ringden et al., 2000). Besides, relapsed 
leukemia after transplantation was successfully treated by a donor lymphocyte infusion 
(Kolb et al., 1990). Due to the fact that the GvT effect appears to be closely associated 
with GvHD, many studies have focused on separating the beneficial GvT effect from 
GvHD, to prevent and control GvHD with the GvT effects being preserved (Kolb, 2008; 
Rezvani and Storb, 2008).  
The GvT effect is mainly mediated by cytotoxic T lymphocytes (CTLs). In the context of 
HSCT, two cytolytic pathways, the Fas-FasL and the perforin-granzyme pathway, are 
thought to be highly relevant for the modulation of GvHD and the GvT effect (Van den 
Brink and Burakoff, 2002). The Fas-FasL pathway seems to be limited to lymphoid 
malignancies compared to the perforin-granzyme pathway in cancer surveillance. In 
addition to effector CD8+ T cells, natural killer (NK) cells also play important roles in 
GvT effects, particularly in the absence of a T-cell mediated setting. Thus, it has been 





while suppressing GvHD (Rezvani and Storb, 2008). Besides NK cells, the infusion of 
regulatory T cells co-cultured with PDL-1 has been found to possess anti-tumor effects 
while suppressing GvHD in an allogeneic HSCT murine model (Stathopoulou et al., 
2018).  
In conclusion, successful HSCT has three consequences: the first one is that the host may 
attack the transplanted cells and induce graft rejection, which is prevented by the 
conditioning regimen; second, the infused cells recognize host cells and tissues as foreign, 
leading to severe or fatal GvHD, and this reaction needs to be controlled; third, the GvT 
effect is closely associated with GvHD; this beneficial effect should be exploited and 
effective approaches are required for the separation of the GvT effect from GvHD. 
 
1.2.3 Pathogenesis of aGvHD 
The occurrence and development of aGvHD is complicated. Many cell types including 
diverse immune cells and even some non-hematopoietic cells are involved (Perkey and 
Maillard, 2018). Various cytokines and chemokines also play a crucial role in the 
pathogenesis of aGvHD (Zeiser et al., 2016). More and more studies have revealed the 
important interactions of commensal microbiota and metabolites in the gastrointestinal 
tract with the severity of GvHD, recently (Koyama et al., 2019; Stein-Thoeringer et al., 
2019; Swimm et al., 2018).  
Based on the substantial knowledge derived from animal models and clinical studies, the 






Figure 1. Pathophysiology of aGvHD. The initiation and development of aGvHD have been 
divided into four phases. In the first phase, tissue damage is triggered by the conditioning 
regimen, leading to the release of pro-inflammatory cytokines stimulated by PAMPs and 
interaction with the gut microbiome. In the next phase, donor T cells become activated with the 
help of host APCs, donor APCs and non-hematopoietic cells, accompanied by the production of 
cytokines (cytokine storm), forming a positive feedback loop. In the third phase, activated allo-T 
cells migrate from the secondary lymphoid organs to the target organs. In the end, the effector 
cells infiltrate the target organs, resulting in end-organ damage, which is the damage to skin, liver 
and gastrointestinal tract, developing into severe GvHD. The figure is adapted from Blazar et al. 
(2012). 
Patients suffering from hematological malignancies receive conditioning regimens, such 
as TBI, that trigger the release of pro-inflammatory cytokines, IL-1β, IL-6 and TNF-α. 
Some studies have demonstrated that the production of these cytokines remains increased 
for at least three months after TBI (Dorshkind et al., 2019). High-dose TBI leads to the 
release of microbial products in gastrointestinal tract, such as lipopolysaccharide (LPS), 
which stimulates the cytokine cascade through innate immune pathways (Hill et al., 
1997). These products derived from the microbiome and intestinal injury are damage-
associated molecular patterns (DAMPs) and pathogen-associated molecular patterns 
(PAMPs) that are recognized by receptors of the innate immune system, resulting in the 
establishment of a pro-inflammatory microenvironment after the conditioning regimen 
(Perkey and Maillard, 2018). It has been shown that conditioning intensity impacts the 





translocation of LPS into the systemic circulation and increased production of TNF-α 
(Hill et al., 1997). In an aGvHD mouse model, the loss of intestinal stem cells (ISCs) was 
found in the initial phase of aGvHD, suggesting that conditioning and alloimmunity can 
target ISCs. During this process, the cytokine IL-22 that is mainly secreted by the innate 
lymphoid cells (ILCs) is critical to reconstitute the intestinal stem cell niche and 
contributes to the integrity of the epithelial barrier (Hanash et al., 2012; Lindemans et al., 
2015). The conditioning regimens cause neutropenia, and those patients who developed 
neutropenic fever showed a reduced mortality, and therefore, had to be treated with 
broad-spectrum antibiotics against Gram-negative bacteria (Hiemenz, 2009). The 
successful gut decontamination with the antibiotics then reduced the severity of GvHD in 
both mouse models (Vaishnava et al., 2011) and some clinical studies (Storb et al., 1983). 
However, it has also suggested that broad-spectrum antibiotics disrupt the homeostasis of 
the intestinal microbiota and reduce microbiota diversity, resulting in an increased GvHD 
severity. Thus, it is required to select more specific antibiotics to prevent damage caused 
by microbiota and to reduce GvHD (Shono et al., 2016). 
In the second phase of GvHD, donor T cells are activated by antigen-presenting cells 
(APCs) and undergo expansion. The conventional dendritic cells (cDCs) are considered 
to be sufficient to prime donor T cells, and GvHD seemed to be driven by recipient APCs 
in a CD8+ T cell-mediated mouse model (Shlomchik, 1999). It has been demonstrated 
that donor APCs can amplify the disease later, and moreover, that GvHD can be induced 
by non-hematopoietic recipient APCs (Koyama et al., 2012). Namely, the expression of 
MHC class II molecules on epithelial cells was up-regulated in the gastrointestinal tract 
in an inflammatory microenvironment, especially created by the early phase of GvHD 
(Koyama et al., 2019). The sites of where allo-T cells get primed remain debatable. The 
naïve cells classically traffic to the secondary lymphoid organs, such as spleen and lymph 
nodes, and become activated by diverse APCs. In addition, fibroblasts have been also 
considered to be capable of driving GvHD in the context of HSCT (Perkey and Maillard, 
2018). Differentiation and expansion of allo-T cells require co-stimulatory signaling, 
such as the crosstalk between CD28 expressed on T cells and CD80 or CD86 expressed 





GvHD, such as Inducible T-cell Costimulator (ICOS) or, 4-1BB (Zeiser et al., 2016). T 
cells can differentiate into several subsets, such as Th1, Th2, and Th17 cells, that produce 
lots of cytokines. These cell types and cytokines have been suggested to impact the 
pathogenesis of GvHD but their contributions are still under investigation (Yi et al., 
2009). 
The next phase is characterized by the migration of the alloreactive T cells to the target 
organs, which is mediated by chemokines, chemokine receptors, and integrins. It has 
been shown that CCR5 is involved in this process and described to recruit effector T cells 
(Palmer et al., 2010). CCR9 expressed by alloreactive T cells facilitates the T cell 
recruitment to gut and skin. CCR4 and CCR10 are critical for skin homing, and CXCR3 
helps to attract Th1 cells to the sites of cellular injury (Blazar et al., 2012). In addition, L-
selectin (CD62L) interacting with integrin α4β7 regulates the homing of T cells to 
mesenteric lymph nodes and Peyer patches in the context of gut GvHD manifestation 
(Dutt et al., 2005). 
The last stage of GvHD involves tissue damage caused by the alloreactive T cells through 
cytolytic pathways and further recruitment of other leukocytes. The cytotoxic activity is 
mainly mediated by two cytolytic pathways: Fas-FasL and perforin-granzyme (Braun, 
1996). MHC class I dependent aGvHD is mostly mediated by the perforin-granzyme 
pathway, while the MHC class II dependent aGvHD is mediated by the Fas-FasL 
pathway (Graubert et al., 1997).  
 
1.2.4 Prevention and treatment to GvHD 
GvHD is the leading cause of transplant-related mortality. Up to 50% of the patients 
undergoing allo-HSCT are clinically affected by aGvHD (Zeiser and Blazar, 2017). The 
clinical organ involvement of aGvHD includes skin, liver and gastrointestinal tract (GI). 
Skin GvHD can be controlled without using systemic immunosuppression and liver 
GvHD is less relevant. GI manifestation of GvHD, however, is the main contributor to 





systemic glucocorticoids (GCs) is the first-line therapy for grade II-IV aGvHD, though 
the main mechanisms are still partially unclear (Sung and Chao, 2013). The aGvHD 
patients are given an initial dose of methylprednisolone or prednisolone at 1-2 mg/kg per 
day and the dose is increased if there is no significant response to the primary treatment. 
Despite their wide use, there are many patients who do not respond to systemic GCs in 
the treatment of aGvHD, which is defined as corticosteroid-refractory or steroid-resistant 
aGvHD (Garnett et al., 2013). It is noteworthy that patients with steroid-resistant aGvHD 
only have an overall survival rate of 5 to 30% (Zeiser and Blazar, 2017). 
Given the critical role of donor T cells in the pathogenesis of aGvHD, many drugs have 
been developed that suppress T cell functions such as cytokines and proliferation, and are 
widely used in clinical setting (Singh and McGuirk, 2016). These include, the calcineurin 
inhibitors cyclosporine, FK-506 for suppression of IL-2 secretion and methotrexate for 
suppression of cell proliferation. Another approach is to deplete T cells contained in the 
graft before transplantation, although this approach compromises GvT effect. To this end, 
CD34+ positive selection ex vivo is carried out to discard T cells. To decrease the relapse 
rate after T cell-depletion, the administration of IL-2 has been performed to boost the 
function of NK cells (Ho and Soiffer, 2001). Selectively depleting T cells, such as CD8+ 
T cell depletion followed by cyclosporine treatment, has been shown to reduce the 
occurrence and severity of GvHD while preserving the GvT effect (Champlin et al., 
1990). Recently, more and more studies have focused on gut microbiota, and approaches 
to maintain the homeostasis of the intestinal microbiota appear to be a promising 
approach to prevent GI GvHD (Shono and van den Brink, 2018), such as probiotic 











1.3.1 Overview of glucocorticoids 
Glucocorticoids (GCs) are a group of steroid hormones with a broad capacity to exert 
anti-inflammatory effect which has been widely used to treat many autoimmune, 
inflammatory and allergic diseases, such as rheumatoid arthritis, asthma, and ulcerative 
colitis (Rhen and Cidlowski, 2005). In contrast, long-term treatment with GCs results in 
adverse effects, such as hypertension, immunosuppression, increased risk of infections, 
osteoporosis, depression and impaired wound healing (Cain and Cidlowski, 2017). The 
discovery of GCs, initially named ‘Compound E’, won Philip S. Hench, Edward Kendall, 
and Tadeus Reichstein the Noble Prize in Physiology or Medicine in 1950. Endogenous 
GCs are generated from cholesterol in the mitochondria within the adrenal cortex through 
a biological process termed as steroidogenesis. The production of GCs is induced by the 
hypothalamic-pituitary-adrenal axis (HPA axis) upon external stimulation and GCs can 
suppress the HPA axis reversely, forming a negative feedback loop to regulate the GCs’ 
production. Stimuli of the HPA axis include mood change, circadian rhythm, pain 
receptor signaling and pro-inflammatory cytokines, such as IL-1, TNF-α, and IL-6. GCs 
exert potent anti-inflammatory effects and reduce the production of these cytokines, 
forming a second negative feedback loop (Dunn, 2000; Rhen and Cidlowski, 2005).  
The bio-availability of GCs is controlled by corticosteroid binding globulin (CBG). Once 
being synthesized in the adrenal cortex, GCs enter the circulation system and bind to 
CBG in the blood, leaving only 5% of GCs in the free bioactive form (Breuner and 
Orchinik, 2002). GCs diffuse into cytosol and their biological activation conditions are 
regulated by two complementary enzymes. Within cells, 11β-hydroxysteroid 
dehydrogenase type 1 (11βHSD1) converts GCs into their active form, e.g. cortisone to 
cortisol, and type 2 11β-hydroxysteroid dehydrogenase (11βHSD2) conversely 
inactivates GCs by catalyzing the opposite reaction (Yang and Zhang, 2004). Many 
synthetic GC derivatives have been developed and are widely used in clinic, such as 
prednisone, beclomethasone, and fluticasone. Compared to endogenous GCs, synthetic 





CBG binding or the conversion mediated by the two 11β-hydroxysteroid dehydrogenases. 
 
1.3.2 Mechanisms of glucocorticoids 
GCs passively diffuse through cell membranes and regulate gene expressions after 
binding to the GC receptor (GR). The GR exists in almost all nucleated cells. Based on 
some studies, GCs can regulate more than 20% of the genome (Galon et al., 2002). In 
humans, the GR is encoded by the gene NR3C1 (Nuclear receptor subfamily 3, Group C, 
member 1) (Figure 2).  
 
Figure 2. Location and genomic structure of the human GR. The GR consists of nine exons 
and is located on chromosome 5. The GR has three transcription initiation sites. Alternative 
splicing at exon 9α or 9β produces two isoforms of GR (GRα and GRβ). The DBD represents the 
DNA-binding domain and the LBD represents the ligand-binding domain. The figure is adapted 
from Rhen and Cidlowski, 2005.  
The GR protein is composed of three functional domains: N-terminal domain, DNA-
binding domain (DBD), and ligand-binding domain (LBD). Nuclear translocation of the 





1998). There are two zinc fingers located at in the DBD, and especially the second zinc 
finger is important for GR dimerization (Vandevyver et al., 2013). Alternative splicing of 
exon 9 results in the generation of the two isoforms: GRα and GRβ. The GRα variant 
binds to GCs and specific DNA regions and regulates the expression of target genes, 
which is the classic subtype. In contrast, GRβ exerts negative effects on GRα and does 
not bind to ligand, thus failing to activate transcription (Rhen and Cidlowski, 2005). It 
has also been shown that a high level of GRβ is associated with GC resistance (Webster 
et al., 2001). In the cytoplasm, the GR resides in an inactive state without binding to its 
ligands. The GR remains stable as a multiprotein complex by binding to other proteins, 
such as heat shock proteins, immunophilins, and other chaperones to prevent degradation 
(Cain and Cidlowski, 2017; Vandevyver et al., 2013). Besides GR, GCs can also bind to 
another receptor, the mineralocorticoid receptor (MR, encoded by the NR3C2 gene), with 
higher affinity. The expression of the MR is more restricted than that of GR, being 
expressed only in certain cell types; high expression of MR is observed in the heart, colon, 
and hippocampus but low expression in leukocytes (Cain and Cidlowski, 2017). 
GCs act via two distinct mechanisms: genomic effects and non-genomic effects. The 
genomic effects of GCs are three-fold: 1) direct binding to target genes, 2) indirect 
interaction with other transcription factors, and 3) binding to composite response 
elements (Ramamoorthy and Cidlowski, 2016) (Figure 3). 
In addition to the regulation of gene expression as homodimers, the GR can function as a 
monomeric protein by cooperating with other transcription factors, so-called “tethering” 
mechanisms, without contacting with DNA (Ratman et al., 2013). It is noteworthy that 
many key transcription factors related to the mediation of inflammation are modulated by 
the GR based on its “tethering” mechanism, including nuclear factor-κB (NF-κB) 
(Reichardt, 2001), activator protein 1 (AP-1) (Tuckermann et al., 1999), and various 
members of the signal transducer and activator of transcription (STAT) (Cain and 
Cidlowski, 2017), leading to transcriptional repression. Another indirect mechanism of 
the GR is based on “composite” response elements. In this way, the GR binds to DNA 
elements that contain both a GRE and the response elements of other transcription factors 






Figure 3. Mechanisms of GC action. GCs can diffuse through cell membranes and bind to the 
GR located in the cytosol. Upon binding to GCs, the GR translocates into the nucleus and exerts 
its functions to alter the expression of target genes (activation or suppression) by directly binding 
to GC response elements (GREs, or negative GREs), by indirectly binding to other transcription 
factors (TF) through protein-protein interactions, or in a composite fashion. The figure is adapted 
from Cain and Cidlowski, 2017.  
The GR exerts its regulatory functions through non-genomic mechanisms as well, by 
interacting with cytoplasmic signaling complexes (Revankar, 2005) or unspecific 
interactions with lipid membranes. GCs achieve their actions mainly through the genomic 
mechanisms in the context of some inflammatory or autoimmune disorders (Wüst et al., 
2008). However, it has also been shown that the ligand-bound GR has an impact on the 







1.3.3 Effects of glucocorticoids on immune cells 
Inflammation and diverse immune reactions are mediated by various types of leukocytes. 
GCs exert their broad anti-inflammatory effects by regulating all the immune cells and  
by impacting the different phases of inflammation, including the initial alarm phase, the 
mobilization phase, and the resolution phase (Cain and Cidlowski, 2017).  
Dendritic cells (DCs) are considered to be the most proficient APC during infection and 
inflammation. DCs present peptide antigens to CD4+ T cells and CD8+ T cells via MHC 
II and MHC I molecules and activate the adaptive immune system. In general, GCs 
inhibit the maturation of diverse subtypes of DCs, including migratory DCs, tissue-
resident DCs, and plasmacytoid DCs; GCs induce DC apoptosis but they do not affect 
apoptosis in monocytes (Moser et al., 1995). It has been noted that GCs increase the 
uptake of antigens by DCs, whereas, they suppress the function of DCs as antigen 
presenting cell. Moreover, it seems that GCs induce the differentiation of DCs towards 
the so-called “tolerogenic” type (Chamorro et al., 2009). These tolerogenic DCs inhibit 
autoimmune diseases and the graft-versus-host response by inducing T-cell anergy, 
suppressing T cells and promoting the differentiation of regulatory T cells (Rutella et al., 
2006).  
Macrophages are derived from monocytes and play a critical role in innate immunity. 
They are characterized by their ability to produce various pro-inflammatory cytokines, 
which makes macrophages an efficient target of GCs. Based on the studies in GR gene 
modified mouse models, it has been demonstrated that the majority of cytokines can be 
suppressed by GCs by dimerization-independent and indirect tethering mechanisms 
(Reichardt, 2001; Tuckermann et al., 2007). Besides the suppressive effects of GCs on 
macrophages, GCs can induce the generation of alternatively activated macrophages (M2 
subtype). M2 macrophages share the feature of high expression of CD163, CD206, and 
tyrosine-protein kinase MER, and the production of anti-inflammatory cytokines, such as 
IL-10 and TGFβ (Martinez, 2008). In the presence of GCs, the gene profile of 
macrophages alters, facilitating to upregulation of these anti-inflammatory genes and 





al., 2008).  
T cells play a central role in cellular immunity. T cells are generated in the bone marrow 
and mature in the thymus. During the maturation of T cells in the thymus, T cells undergo 
a series of changes from the stage of double negative (DN, CD4- CD8-), and double 
positive (DP, CD4+ CD8+) T cells to the final stage of single positive (SP, CD4+ or 
CD8+) T cells. Positive and negative selection occurs at the double-positive stage. The 
positive selection is mediated by T cell receptor signaling triggered apoptosis, and in 
vitro and in vivo studies revealed that thymocytes are sensitive to GC-induced apoptosis 
(Tuckermann et al., 2005). At the stage of T cell activation and expansion, GCs can 
mediate expression of several kinases that play important roles in T cell signaling, such 
as ITK, TXK, and LCK (Petrillo et al., 2014). It was found that the non-genomic 
mechanism of GCs is also involved in TCR signaling by reducing the activity of LCK 
and FYN (Löwenberg et al., 2007). Upon encountering antigens, T cells become 
activated and differentiate into several subsets, including Th1 cells, Th2 cells, Th17 cells 
and regulatory T cells (Treg). GCs alter the expression of various genes related to these T 
helper cell subtypes and generally shift Th1 cellular immunity to Th2 humoral immunity 
(Ramírez et al., 1996). GCs inhibit Th1 response by down-regulating the production of 
IL-12, suppressing expression of the IL-12 receptor on T cells, reducing the expression of 
T-bet which is the characteristic transcription factor of Th1 cells, and promoting the 
production of  Th2 cytokines, such as IL-4, IL-10, and IL-13 (Elenkov, 2004; Liberman 
et al., 2007). It has been demonstrated that Th17 cells play critical roles in many 
autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis, and the 
mechanisms of the treatment with GCs in these diseases are linked to targeting Th17 cells; 
it has been shown that IL-17 deficient mice are resistant to GC treatment (Baschant et al., 
2011) and that GC treatment triggers apoptosis of Th17 cells in the context of a mouse 
model of experimental autoimmune encephalomyelitis (Wüst et al., 2008). Studies in 
mice and humans revealed that GCs also affect regulatory T cells through enhancing Treg 
activity and differentiation and resistant to GC-induced apoptosis (Chen et al., 2003). The 
enhanced activity of Treg cells might be due to the upregulation of FoxP3, the master 





(Bereshchenko et al., 2014).  
 
1.3.4 Targeted delivery of glucocorticoids 
GCs are the first-line therapy of choice for many inflammation-related diseases based on 
their broad immuno-suppressive abilities on various leukocytes as mentioned above. 
However, high-dose and/or long-term treatment with GCs, as well as steroid-resistance, 
result in serious adverse effects, which constrains their use and contributes to treatment 
failure (Kaiser et al., 2020a; Montes-Cobos et al., 2017). Therefore, increasing drug 
sensitivity and reducing treatment side-effects are in an urgent need. One promising 
approach or an attempt to achieve this is to innovate and improve drug delivery systems. 
In recent years, various drug delivery systems have been reported, such as liposomes, 
nanoparticles, and inorganic scaffolds (Lühder and Reichardt, 2017). Liposomes are 
biocompatible vesicles that have been modified on their surface to inhibit immediate 
phagocytosis and increase their bio-stability in the blood circulating system. One example 
is the modification with polyethylene glycol (PEG). Due to their size, these PEGylated 
liposomes can passively target tumors and inflammation sites, and further accumulate 
there based on the so called “enhanced permeability and retention effect” (EPR) (Maeda 
et al., 2001). However, the disadvantage of this application strategy is that liposomes can 
also cause the stimulation of the complement system in patients (van den Hoven et al., 
2013). Another delivery method of GCs is the use of polymeric micelles. They are 
spherical, colloidal NPs with a core-shell structure (Jhaveri and Torchilin, 2014), 
consisting of a hydrophilic corona and a hydrophobic core that is loaded with the drug. 
Encapsulated drugs in the core of polymeric micelles remain solubilized and are slowly 
released, thus being protected from degradation. There is another delivery strategy called 
polymer-drug conjugates, where the active compounds are covalently bound to a 
macromolecular carrier, leading to conjugates that stabilize the drugs in blood. The most 
popular example of this category is N-(2-hydroxypropyl) methacrylamide (HPMA) 
copolymers (Lammers, 2010). In addition to these delivery systems, which are based on 
organic molecules, compounds can also be encapsulated and delivered by a variety of 





2011). However, this delivery system has the limitation of a low drug load (Lühder and 
Reichardt, 2017). 
An alternative to the existing delivery systems is the application of novel inorganic-
organic hybrid nanoparticles (IOH-NPs). IOH-NPs possess a general composition of 
[M]2+ [Rfunction(O)PO3]
2- (M = ZrO, Mg2O; R = functional organic group), and show 
multipurpose and multifunctional properties after being loaded with drugs or fluorescent 
dyes, which gained them a lot of interest in theranostics (Heck et al., 2015). IOH-NPs are 
insoluble in water due to their inorganic cation, and they allow a load of active drug up to 
80%. It has been demonstrated that IOH-NPs are distributed from the peritoneal cavity, 
accumulate in the abdominal organs, such as liver, small intestine, and stomach, and are 
finally excreted via the intestinal tract after mice were intraperitoneally injected with 
them. Moreover, IOH-NPs are selectively taken up by different cell types in vitro, 
preferentially by myeloid cells and fibroblasts, which was shown to predominately occur 
via the micropinocytosis pathway (Kaiser et al., 2020a). One of the biologically 
functional forms of IOH-NPs is [ZrO]2+-[(BMP)0.9(FMN)0.1]
2- (BMP = betamethasone 
phosphate; FMN = flavin mononucleotide, termed BMP-NPs). It has been reported that 
BMP-NPs were preferentially taken up by macrophages, and that the administration of 
BMP-NPs shifted the phenotype of macrophages from the classically inflammatory (M1) 
type to the alternatively activated (M2) type in vitro via upregulating RNA levels of 
CD163, and Ym1, and reducing the expression of MHC class II, and CD86 on the cell 
surface. Besides, in a moues model of multiple sclerosis, the efficacy of BMP-NP therapy 
was lost in mice with a GR-deficiency in myeloid cells (GRlysM), while being preserved 
in mice with a GR-deficiency in T cells (GRlck) or brain endothelial cells (GRslco1c1) 












Allogeneic HSCT is one of the most effective approaches to treat various leukemias and 
lymphomas, but it is accompanied by the development of life-threatening aGvHD. Much 
effort has been made to avoid and prevent this fatal disease by targeting the allogenic T 
cells that play a major role in the pathogenesis of the aGvHD. 
Clinically, patients suffering from aGvHD are administered high-dose GCs, a potent anti-
inflammatory agent. However, many patients do not respond to the treatment with GCs, 
and those patients who develop such refractory aGvHD show a low rate of non-relapse 
survival. Importantly, the mechanisms of GC-resistance remain poorly understood and 
better insights would allow to improve the available therapy. In addition, biomarkers for 
refractory aGvHD that may serve to predict long-term outcome are urgently needed, and 
also the discovery of new potential target genes for the prevention or treatment of aGvHD 
is highly required. Hence, GC-resistant aGvHD mouse models were used to identify new 
genes that are linked to a successful treatment of the disease. 
Allogeneic T cells are the main driver of aGvHD but they are also responsible for the 
beneficial GvT effect. We have successfully used GC-loaded IOH-NPs in our group to 
treat aGvHD in a mouse model and found that they show an increased cell-type 
specificity, since they are preferentially taken up by macrophages but hardly at all by T 
cells. Therefore, we tested whether GC treatment using IOH-NPs has the potential to 
ameliorate aGvHD while preserving the GvT effect of the graft. 
This thesis had two main aims: 
o To identify new target genes in the context of GC-resistant aGvHD in mice, that can 
be used as predictive biomarkers or potential therapeutic targets. 
 
o To assess the GvT effect after GC treatment of aGvHD in mice with IOH-NPs, and 
to test the cytotoxic ability of the CD8+ T cells in this model. 




2. Material and Methods 
2.1 Material 
2.1.1 Instruments 
If not specifically declared, the manufacturers are located in Germany. 
Table 1. Instruments 
Equipment Supplier 
Akku-jet® pro pipette controller Brand GmbH, Wertheim 
Axio Scope A1 Zeiss, Jena 
Axio Scope Aplus Zeiss, Jena 
BD FACS Canto II BD Biosciences, Heidelberg 
BioTek® Power Wave 340 Plate Reader BioTek Instruments, Wetzlar 
Cell Incubator, HERACell 240 Heraeus, Hanau 
Centrifuge 2-5 Sigma Laborzentrifugen, Osterode 
Centrifuge 5417R Eppendorf, Hamburg 
Centrifuge 5804R Eppendorf, Hamburg 
EasyPet 3 Eppendorf, Hamburg 
EasySep™ Magnet STEMCELL Technologies, SARL, 
Cologne 
Electrophoresis power supply 301 Amersham Biosciences, Freiburg 
Fluidigm BioMark™ Life Technologies Corporation, South 
San Francisco, California, USA 
Freezer Hera freeze -80 ºC Heraeus, Hanau 
Freezer Liebherr Comfort -20 ºC Liebherr-International Deutschland 




GmbH, Biberach an der Riss 
Freezer VIP plus -150 ºC SANYO Electric Co., Ltd, Moriguchi, 
Osaka, Japan 
IFC Controller MX Life Technologies Corporation, South 
San Francisco, California, USA 
Infrared Lamp Balance 100W Philips, Amsterdam, the Netherlands 
Laminar airflow cabinet, HERASafe Heraeus, Hanau 
Microscope Primo Star Zeiss, Jena 
Microscope Telaval 31 Zeiss, Jena 
Microtom SM2000R Leica Biosystems, Wetzlar 
Microwave R-212 Sharp, Osaka, Japan 
Multichannel pipette S-12, 20-200 µl Brandt, Wertheim 
Nanodrop 2000 Peqlab Biotechnology, Erlangen 
Neubauer improved haemocytometer Henneberg-Sander GmbH, Giessen-
Lützellinden 
Nunc™ Immuno Wash 12 Thermo Fisher Scientific, Wilmington, 
DE, USA 
pH-Meter 766 Calimatic Knick Elektronische Messgeräte GmbH 
& Co.KG, Berlin 
Pipettes Eppendorf Research plus 2.5 µl, 
20 µl, 200 µl, 1000 µl 
Eppendorf, Hamburg 
Real-Time PCR System 7500 Applied Biosystems, Foster City, CA, 
USA 
Rotilabo® mini-centrifuge Carl Roth GmbH & Co.KG, Karlsruhe 
RS 225 X-Ray Research System Gulmay Medical Systems, Camberley, 
Surrey, UK 




Scale Acculab ALC-3100.2 Sartorius, Göttingen 
Scale TE313S Sartorius, Göttingen 
Shaker GFL 3006/3005 Gesellschaft für Labortechnik, 
Burgwedel 
Thermocycler Mastercycler EP Gradient Eppendorf, Hamburg 
Thermomixer Comfort Eppendorf, Hamburg 
Tissue Homogenizer Ultra Turrax T18 
Basic 
IKA, Staufen 
Tissue Processor Excelsior ES Thermo Fisher Scientific, Wilmingon, 
DE, USA 
Tissue Tek Prisma Slide Stainer Sakura Finetek. Staufen 
UV System with camera, Gel Imager 
(Chemostar) 
INTAS, Science Imaging Instruments 
GmbH, Göttingen 
VARIOMAG® Power direct magnetic 
stirrer 
Thermo Fisher Scientific, Waltham, 
USA 
Vortex Genie-2 Scientific Industries, Bohemia, New 
York, USA 
Water bath W12 Labortechnik Medingen, Dresden 
Water Purification System Arium Pro Sartorius, Göttingen 
 
2.1.2 Consumables 
Table 2. Consumables 
Consumable Supplier 
BD Falcon 5 ml Polystyrene tubes with 
Cell-strainer Cap 
BD Biosciences, Heidelberg 




BD Micro-Fine + Demi U-100 Insulin 
Syringes (0.3 ml, 30G) 
BD Biosciences, Heidelberg 
BD Microlance™ 3 (20G 1.5) BD Biosciences, Heidelberg 
BD Microtainer® SST™ tubes BD Biosciences, Heidelberg 
Cellstar Culture Plates (6-well, 12-well, 
24-well) 
Greiner bio-one GmbH, Frickenhausen 
CELLSTAR PS Cell Culture dishes 10 
cm 
Greiner bio-one GmbH, Frickenhausen 
CELLSTAR serological pipettes (5 ml, 
10 ml, 25 ml) 
Greiner bio-one GmbH, Frickenhausen 
CryoTube™ Vials Nunc, Rosklide, Denmark 
EASYstrainer™ (40 µm, 100 µm) Greiner bio-one GmbH, Frickenhausen 
Falcon 5 ml Polystrene tubes, non-
sterile 
Th. Geyer GmbH & Co. KG, Renningen 
Falcon tubes (15 ml, 50 ml) Greiner bio-one GmbH, Frickenhausen 
Filter paper 66 × 24 mm DiaTec, Bamberg 
Fluidigm 48.48 Dynamic Array™ IFC Life Technologies Corporation, South 
San Francisco, California, USA 
Fluidigm Control line fluid Life Technologies Corporation, South 
San Francisco, California, USA 
Glas pipettes (10 ml, 25 ml) Brand GmbH, Wertheim 
Hypodermic needle Sterican® 26G × 
0.5, 24G × 1 
B Braun, Melsungen 
MacrOflow Tissue cassettes Th, Geyer GmbH & Co. KG, Renningen 
Microscope Cover Slips, 24 × 60 mm Menzel-Gläser, Braunschweig 
Microscope Slides SuperFrost Plus Menzel-Gläser, Braunschweig 




Multiply® Pro 8-Strip PCR Microtubes Sarstedt, Nümbrecht 
Nunc-Immuno™ Microwell™ 96 well 
plates 
eBioScience, San Diego, USA 
Optical Adhesive Covers Applied Biosystems, Foster city, USA 
Parafilm Bemis, Neeth, WI, USA 
Pipette tips (10 µl, 200 µl, 1000 µl) Greiner bio-one GmbH, Frickenhausen 
PP tubes sterile 14 ml Greiner bio-one GmbH, Frickenhausen 
Reaction tubes, PP natural (1.5 ml, 2 ml) Greiner bio-one GmbH, Frickenhausen 
Saphire Microplate, 96 well for qPCR Greiner bio-one GmbH, Frickenhausen 
Syringe BD Discardit™ II (2 ml, 5 ml) BD Biosciences, Heidelberg 
 
2.1.3 Reagents and Chemicals 
Table 3. Reagents and chemicals 
Reagent and chemical Supplier 
3,3’, 5,5’-Tetramethylbenzidin Sigma-Aldrich Chemie GmbH, 
Taufkirchen 
Assay Loading Reagent 2 × Life Technologies Corporation, South 
San Francisco, California, USA 
BD FACS Clean solution BD Biosciences, Heidelberg 
BD FACS Flow Sheath fluid BD Biosciences, Heidelberg 
BD FACS Shutdown solution BD Biosciences, Heidelberg 
Betamethasone phosphate nanoparticles 
(BMP-NPs) 
Prof. Dr. Klaus Feldmann, Institute of 
Inorganic Chemistry KIT, Karlsruhe 
Bovine serum albumin Carl Roth GmbH & Co.KG, Karlsruhe 




Chloroform Sigma-Aldrich Chemie GmbH, 
Taufkirchen 
Citric acid Carl Roth GmbH & Co.KG, Karlsruhe 
Dimethylsulfoxid 99.8% Carl Roth GmbH & Co.KG, Karlsruhe 
Disodium hydrogen phosphate Carl Roth GmbH & Co.KG, Karlsruhe 
Dithiothreitol Sigma-Aldrich Chemie GmbH, 
Taufkirchen 
DNA Binding Dye 20 × Life Technologies Corporation, South 
San Francisco, California, USA 
Empty nanoparticles (EP-NPs) Prof. Dr. Klaus Feldmann, Institute of 
Inorganic Chemistry KIT, Karlsruhe 
Ethanol 99.8% Carl Roth GmbH & Co.KG, Karlsruhe, 
Chemsolute® Th. Geyer GmbH & Co. 
KG, Renningen 
Ethidiumbromide solution Carl Roth GmbH & Co.KG, Karlsruhe 
Ethylendiaminetetraacedic acid Sigma-Aldrich Chemie GmbH, 
Taufkirchen 
Exonuclease I Reaction Buffer 10 × NEW ENGLAND, BioLabs®, UK 
F-518 Phusion® HF buffer with 7.5 mM 
magnesiumchlorid 
Thermo Fischer Scientific, Waltham,  
USA 
Fetal calf serum Abbvie, Ludwigshafen 
Gene Ruler 1kb DNA ladder Thermo Fischer Scientific, Waltham,  
USA 
Gibco® 2-Mercaptoethanol Thermo Fischer Scientific, Waltham,  
USA 
Gibco® RPMI1640 + GlutaMAX™ Thermo Fischer Scientific, Waltham,  





Glycerol Carl Roth GmbH & Co.KG, Karlsruhe 
Hydrogen Peroxide 30% Carl Roth GmbH & Co.KG, Karlsruhe 
Neomycin trisulfate salt hydrate Sigma-Aldrich Chemie GmbH, 
Taufkirchen 
Nucleoside triphosphate Genaxxon bioscience, Ulm 
OptiLyse® B Lysing solution Beckman Coulter, Inc., France 
Orange G sodium salt Sigma-Aldrich Chemie GmbH, 
Taufkirchen 
Paraffin wax Sigma-Aldrich Chemie GmbH, 
Taufkirchen 
Paraformaldehyde, 4% Carl Roth GmbH & Co.KG, Karlsruhe 
PegGOLD Universal Agarose Peqlab Biotechnology GmbH, Erlangen 
Penicillin/Streptomycin (10.000 U/ml) Invitrogen, Carlsbad, CA, USA 
Potassium chloride Merck KGaA, Darmstadt 
Potassium dihydrogen phosphate Merck KGaA, Darmstadt 
Power SYBR® Green Master mix Applied Biosystems, Foster City,  
USA 
QIAzol™ Lysis buffer Qiagen, Hilden 
Sodium carbonate Merck KGaA, Darmstadt 
Sodium chloride, 99.5% Carl Roth GmbH & Co.KG, Karlsruhe 
Sodium hydrogen carbonate Merck KGaA, Darmstadt 
SsoFast EvaGreen Supermix with low 
ROX 2 × 
Bio-Rad Laboratories GmbH, Munich 
Sulfuric acid, 95-98% Merck KGaA, Darmstadt 




TaqMan® PerAmp Master mix 2 × Applied Biosystems, Foster City,  
USA 
Tween® 20% Carl Roth GmbH & Co.KG, Karlsruhe 
 
2.1.4 Buffers 
Table 4. Buffers 
Buffer Component 
DNA Suspension buffer 10 mM Tris 
0.1 mM EDTA in ddH2O, pH 8.0 
EasySep™ Recommended medium 2 % FCS 
1 mM EDTA in PBS 
ELISA Assay diluent 10 % FCS in PBS 
ELISA Coating buffer 1000 ml ddH2O 
8.4 g NaHCO3 
3.56 g Na2CO3, pH 9.5  
ELISA Developing solution ELISA Substrate buffer 
1 % TMB in DMSO 
0.2 % H2O2 
ELISA Stop solution 1 M H2SO4 in ddH2O 
ELISA Substrate buffer 0.1 M Citric acid 
0.2 M Na2HPO4 in ddH2O 
ELISA Washing buffer 0.05 % Tween® 20 % in PBS 
FACS buffer 0.1 % BSA 
0.01 % Sodium azide in PBS, pH 7.2 
Orange G Loading dye 100 ml ddH2O 
100 mg Orange G sodium salt 
30 % Glycerol 




Phosphate saline buffer (PBS) 137 mM NaCl 
2.7 mM KCl 
10 µM Na2HPO4 
2 mM KH2PO4 in ddH2O 
TAC buffer 20 mM Tris 
155 mM NH4Cl in ddH2O 
TAE buffer 40 mM Tris 
20 mM Acetic acid 
1 mM EDTA in ddH2O 
 
2.1.5 Primers 
Table 5. Primers 




Acaca ATG GGC TGC TTC TGT GAC TC 





GAC AAG AAG AGC TTC ATT CCC GTG 
CAT CAG CAT AGA ACT CGC TCT TCC 




ACC GCA GGT CCT CAG GAT G 







CAG ATG GGT CCA GCT TCA AC 







GTC ACT TGG GCC AGG TAT CC 







AGC CCG AGC ACA TGC AGC AG 





Arg2 TCC TTG CGT CCT GAC GAG ATC CG NM_009705.3  150 




 AGG TGG CAT CCC AAC CTG GAG AG   
Ccl2 
 
CAC TCA CCT GCT GCT ACT CA 







ATA TGG AGC TGA CAC CCC GA 







CTC ACC ATA TGG CTC GGA CA 







CCC TGG GAA GCT GTT ATC TTC AA 







AGG AGC CAT ACC TGT AAA TGC C 







CAG AGA ACA CCA CCG CTG TA 







CGC CTG CAG ATA GTT CCC AA 







GGC TCT TTG TGT TAT CTG GAC AAA 







ACT TTG ATG GCC TCA ACC TG 







CCA CTC TGT CCA CAT TGC CT 







TGA CTA TGT GTC CTG TGG CG 







AGT GCT CTA GCC GAG ATG TG 






CAG GGT CTA CGG GGC AAT TT 










ACG CAG ATT TAT GTC ATT GAT CCA G 






AGA CCA TGG CTG GGA TTC AC 






CCA CGT GTT GAG ATC ATT GCC 







CAG CTG CTC AAG GCT TCC TTA 






GCC TCT CTC CGA GCC ACG GTA 






TGA ACA AAG GCA AGG CTA ACT G 






CCC TAC GGT GGA AGT CAT AGC 






GCC ATG AAG TCC GCT GTT CT 






ACT GGG CTT CTC TTC TGA TGC 






GGG AAC TGG GCT GTG AAT GA 






CTC CAA GGA GGA TAT GAA GCG 






CTC TGG CTA CCA CTA CGG TG 






CTG GGT TGT ACT TCG TGT ATT CC 




Gilz GGA GGT CCT AAA GGA GCA GAT TC NM_001077364.1 80 




 GCG TCT TCA GGA GGG TGT TC  
Gzmb 
 
TGT GGG CCC CCA AAG TGA CAT 






TGA TTC TGG GGG TCC TCG CCC 






CAC AGA AAT GGC CCA GTG AGA 







GCC TCG GTT TCT CTA TTT GGC 






ACG TGG TGT GTC TAT TCG CC 






AGG CTT TAA GCT GGT GAT GGC 






GTC CTG TGG CCA TCT GCC TA 






ACT GGC AAA AGG ATG GTG AC 






AGG CAG AGA AGC ATG GCC CA 






GCT CAG CTC CTG TCA CAT CA 






TCC AGA AGG CCC TCA GAC TA 






AAC CAC CCA CAA CGA TCC TG 






CTC ATC TGG GAT CCT CTC CA 










CAG CCA GTG TTT ATT TGC TCA G 






ACT TGC CCA AGC AGA CCA CA 






TTC CTG TCT GTA TTG AGA AAC CT 






AGT TGC CTT CTT CGG ACT GA 






CTT CCA CTT CCC GAT CTG CAT 






CAT CCC CCT GCA AGT ACC TC 






CCC AGG AAT GCA CCA AGT ACA 






AAA CAA ATG ACA GCC CCA AGC 






GCT GGT TAA GTC CTA TCA CTG G 






GCA AAC TTA ACT GCC CCG TG 






AAT TGG TCA GGA CAA GGG CT 






TCG ACC CAA TAC TCT CCG CT 






CAG CTA CCC CAG CTC ACA TC 




Myc TTG GAA ACC CCG CAG ACA G NM_010849.4 88 




 GCT GTA CGG AGT CGT AGT CG  
Nos2 
 
GGT GAA GGG ACT GAG CTG TT 






ATT GGT GCG GCT GTC CTA AA 






TGC TGC AAA ATT CGG GAT GC 






AGA TGA TTG CCG CTG TAT CC 






GTC GCC GAA TAC AGC TAC GA 






CTA CGT GAA GGA TCT GGT GGT 






AGT CCC ATA CAC AAC CGC AG 






TGT TAA AGT TGC GGG GGA GGG C 






CAG GAA GAT TGT ACG CAG GC 






GAA GAA GGC TTT TGC CAA CCC 




Ptgs2 CAG ACA ACA TAA ACT GCG CCT T 






CTT GCC AAC CAG ACA GGT CA 






CTT GAG CGA GGC TGC TGT TT 










CGC TAT CGT CTT TGG TGT GG 




Slc2a1 AGC ATC TTC GAG AAG GCA GG 




Slc2a3 CTC TTC AGG TCA CCC AAC TAC GT 






GGG GAA GGA CAT GGG ACA AG 






ACA GTG GGC ACC TTC TTT C 






TGG TTG CAG AAA ATG CCA GG 






ATG GCC TCC CTC TCA TCA GT 






CAG CAC AGA GAG CTG ACA GG 





2.1.6 Fluorochrome-conjugated monoclonal antibodies 
Table 6. Antibodies 
Antibody Clone name   Supplier 
APC anti-mouse CD8α 53-6.7 BioLegend, San Diego, USA 
APC anti-mouse CXCR3 CXCR3-173 BioLegend 
APC anti-mouse EpCam G8.8 BioLegend 
APC anti-mouse Foxp3 FJK-16s eBioscience, San Diego, USA 
APC-Cy7 anti-mouse CD25 PC61 BioLegend 




APC-Cy7 anti-mouse CD62L MEL-14 BioLegend 
APC-Cy7 anti-mouse Gr-1 RB6-8C5 BioLegend 
FITC anti-mouse CD49d R1-2 BD Biosciences, Franklin Lakes, 
USA 
FITC anti-mouse TCR-β  H57-597 BD Biosciences 
PE anti-mouse CD44 IM7 BD Biosciences 
PE anti-mouse CD45.1 A20 BD Biosciences 
PE anti-mouse CD45R/B220 RA3-6B2 BD Biosciences  
PE anti-mouse Igλ RML-42 BioLegend 
PE-Cy7 anti-mouse CD11a 2D7 BD Biosciences 
PE-Cy7 anti-mouse CD11b M1/70 BioLegend 
PerCP anti-mouse CD4 RM4-5 BioLegend 
PerCP-Cy5.5 anti-mouse 
CD45.2 
104 BD Biosciences 
 
2.1.7 Commercial kits and Enzymes 
Table 7. Commercial kits and enzymes 
Commercial kit Manufacture 
EasySep™ Mouse APC positive 
selection kit II 
STEMCELL™ Technologies SARL, 
Cologne 
EasySep™ Mouse CD8+ T cell isolation 
kit 
STEMCELL™ Technologies SARL, 
Cologne 
EasySep™ Mouse CD90.2 positive 
selection kit II 
STEMCELL™ Technologies SARL, 
Cologne 
EasySep™ Mouse T cell isolation kit STEMCELL™ Technologies SARL, 





ELISA MAX™ Standard set mouse 
IFNγ 
BioLegend, San Diego, USA 
ELISA MAX™ Standard set mouse IL6 BioLegend, San Diego, USA 
ELISA MAX™ Standard set mouse 
TNFα 
BioLegend, San Diego, USA 
Foxp3 Staining Buffer set eBioscience®, San Diego, USA 
iScript™ cDNA Synthesis kit Bio-Rad Laboratories GmbH, Munich 
Qiagen RNeasy Plus Universal Mini kit Qiagen, Hilden 




Table 8. software 
Software Company  
7500 System SDS software version 
1.4.0.25 
Applied Biosystems, Foster City, CA, 
USA 
BD FACS Diva™ software version 
6.1.2 
BD Biosciences, Heidelberg 
BioMark™ Data collection software Life Technologies Corporation, South 
San Francisco, California, USA 
BioMark™ Real-Time PCR analysis 
software 
Life Technologies Corporation, South 
San Francisco, California, USA 
BioTek® Gen 5 version 1.09.8 BioTek Instruments, Bad Friedrichshall 
FlowJo version 10 and 7.6.5 Tree Star, Inc., Ashland, USA 




GraphPad Prism 5 GraphPad Software, La Jolla, CA,  
USA 




2.2.1 Mice and housing conditions 
C57BL/6 and BALB/c wild type mice used for the experiments were purchased from 
Janvier Labs (St. Berthevin, France). B6.SJL-PtprcaPepcb/BoyJ (CD45.1-congenic 
C57BL/6) mice were originally obtained from Charles River (Sulzfeld, Germany) and 
kindly provided by Dr. Fred Lühder (Institute of Neuroimmunology). 
All genetically modified mice used in the experiments are listed in the following: 
Nr3c1tm2Gsc mice on the genetic background of C57BL/6 or BALB/c strains (designated 
as GRflox), Nr3c1tm2GscTg(Lck-cre)1Cwi mice on the C57BL/6 genetic background (designated 
as GRlck) and Nr3c1tm2GscLyz2tm1(cre)lfo/J mice on the BALB/c genetic background 
(designated as GRlysM). GRlck mice are characterized by a lack of the GR in the entire T 
cell lines (Theiss-Suennemann et al., 2015) and GRlysM mice are characterized by the 
absence of the GR in the majority of myeloid cells (Baake et al., 2018). GRflox litter mates 
from each strain were used as a control for their knock-out counterparts. 
All mice were bred and kept in the animal facility of the University Medical Center 
Göttingen, and housed in individually ventilated cages under specific-pathogen-free 
conditions (SPF) in a 12-hour light/dark cycle. Food and water were supplied ad libitum. 
Mice were used at the age of 8-12 weeks. All animal experiments were performed 
according to national and international guidelines and approved by the responsible 
authority of Lower Saxony (Niedersächsisches Landesamt für Verbraucherschutz und 
Lebensmittelsicherheit). 
 




2.2.2 The acute GvHD mouse model 
This mouse model is based on a complete mismatch of MHC molecules between donor 
and recipient. To induce aGvHD, bone marrow cells and splenic T cells are isolated from 
C57BL/6 mice (H-2b), which are used as donors, and injected into BALB/c mice(H-2d), 
which are used as recipients, via the tail vein. 
2.2.2.1 Induction of aGvHD 
2.2.2.1.1 Experimental set-up 
Female wild type, GRflox or GRlysM BABL/c mice were used as recipients and given 
neomycin (25 μg/ml) via the drinking water starting two days (-2 day) before bone 
marrow transplantation (BMT). The drinking water containing neomycin was refilled 
every two days during the entire aGvHD experiment. One day before BMT (-1 day), the 
recipient mice underwent total body irradiation at a dose of 8.5 Gy using an X-Ray 
source at 200 kV, 15 mA and 0.5-mm Cu filtration. On day 0, cell transplantation was 
performed, 1 × 107 T-cell-depleted (TCD) bone marrow cells and 2 × 106 splenic T cells 
isolated from wild type, donor GRlck or GRflox C57BL/6 donor mice, and injected into 
recipient BALB/c mice intravenously. The mice only transferred with TCD-bone marrow 
served as controls. The induction of aGvHD using GRlysM recipient mice was performed 
by my colleague Tina Kaiser. 
 





Figure 4. Experimental schematic of acute GvHD induction in mice. 
 
 
Figure 5. Cell type-specific knock-out aGvHD mouse models. 
 
2.2.2.1.2 T cell depletion of bone marrow cells 
The donor mice were euthanized with CO2, and tibia, femura and humeri were collected. 
Bone marrow cells were flushed out of the bones using a 5 ml syringe with a 24 G needle 
filled with PBS + 0.1% BSA. The bone marrow cells were passed through a 40 μm cell 
strainer into a 50 ml Falcon tube and centrifuged at 300 × g for 7 min at 4 °C, the pellets 
were resuspended in the recommended medium (PBS + 2% FCS and 1mM EDTA) and 
adjusted to a concentration of 1 × 108 cells/ml. T cells were depleted from bone marrow 




cells with the EasySep™ positive selection Mouse CD90.2 Kit II according to the 
manufacturer’s instructions. Briefly, a cocktail containing component A (25 μl/ml) and B 
(25 μl/ml) was prepared and incubated at room temperature (RT) for 5 min, subsequently 
added to the sample in a FACS tube (50 μl/ml) for incubation of 3 min. RapidSpheres™ 
was added and left for 3 min at RT, the recommended medium was added to top up the 
sample to 2.5 ml and mixed by gently pipetting up and down 2-3 times. Then the FACS 
tube was placed into the EasySep™ magnet and incubated for 3 min at RT and CD90.2- 
cells were poured to another 50 ml Falcon tube. The cells were centrifuged (300 × g for 7 
min at 4 °C), resuspended in an appropriate volume, counted and adjusted to 1 × 108 
cells/ml with PBS for injection. The recipient mice were injected with 100 μl of the final 
cell suspension along with the purified T cells or PBS. 
2.2.2.1.3 Splenic T cell purification 
Spleens were removed from the donor mice after the collection of the bones. Splenic cell 
suspensions were prepared using a 40 μm cell strainer under sterile conditions, and 
centrifuged at 300 × g for 7 min at 4 °C, and subsequently the pellets were resuspended 
in the recommended medium. T cells were then purified with the EasySep™ negative 
selection Mouse T cell Isolation Kit according to the manufacturer’s protocol. In brief, 
the cells were counted and adjusted to a concentration of 1 × 108 cells/ml. The samples 
were placed in FACS tubes; Normal Rat Serum (50 μl/ml) and Mouse T cell Isolation 
Cocktail (50 μl/ml) were added, and incubated at RT for 10 min. Then the 
RapidSpheres™ (75 μl/ml) was added to the samples, and left at RT for 2.5 min. The 
samples were filled up to 2.5 ml using the recommended medium and placed in the 
magnet for 3 min. The desired fraction was poured into a new 50 ml Falcon tube, 
centrifuged (300 × g for 7 min at 4 °C), resuspended in an appropriate volume, counted 
and adjusted to a concentration of 2 × 107 cells/ml with PBS. Each recipient mouse 
received 100 μl of the final cell suspension. For the mice receiving BM only, PBS was 
added up to 200 μl instead. 




2.2.2.1.4 Quality control of TCD-bone narrow cells and splenic T cells 
The purity of the isolated TCD-bone marrow cells and splenic T cells was determined by 
flow cytometry. The gating strategy is shown in the Figure below. 
 
 
Figure 6. Gating strategy used for the quality control of T cell-depleted bone marrow cells 
(A) and purified T cells (B) by flow cytometry. Isolated bone marrow cells and T cells were 
stained with specific fluorochrome-conjugated antibodies: anti-B220 (for B cells) and anti-TCRβ 
(for T cells), and used for flow cytometric analysis. 
 
2.2.2.1.5 Assessment of the severity of aGvHD 
The severity and progress of aGvHD were assessed starting on day 2 after bone marrow 
transplantation based on an established clinical scoring system (Theiss-Suennemann et al., 
2015). Five parameters were involved in the scoring system: 1) posture, 2) activity, 3) fur 
texture, 4) diarrhea and 5) weight loss. Each parameter was assigned a grade between 0 
(no symptoms) to 2 (severe symptoms), resulting in a total score of 0 to 10. For ethical 
reasons, mice with a clinical score of at least 7 or a weight loss of more than 20% were 
sacrificed. 




Table 9. Acute GvHD clinical score system 
Parameter 0 1 2 
Posture Normal Hunching Impaired movement 
Activity Normal Less active Stationary 
Fur texture Normal Ruffling Absent grooming 
Diarrhea None Mild Severe 
Weight loss 0 % - 10 % 10 % - 20 % More than 20 % 
 
2.2.3 Combined aGvHD/GvL mouse model 
2.2.3.1 Experimental set-up 
2.2.3.1.1 Acute GvHD induction 
Wild type BALB/c recipient mice were given neomycin and subjected to a total body 
irradiation as described before (2.2.2.1.1). TCD-bone marrow cells (2.2.2.1.2) and splenic 
T cells (2.2.2.1.3) were purified from wild type C57BL/6 donor mice and transferred into 
the recipient mice to induce aGvHD (2.2.2.1.1). 
 
2.2.3.1.2 Adoptive B cell lymphoma transfer 
Bcl1 cells (Warnke et al., 1979) were freshly thawed on day 0, corresponding to the time 
point of aGvHD induction. Bcl1 cells were rapidly thawed in a water bath at 37 ºC, 
centrifuged at 300 × g, 5 min at 4 °C, and the pellet washed with 3 ml PBS. The samples 
were then centrifuged again, resuspended, counted, and adjusted to a final concentration 
of 3 × 104 cells/ml. 3 × 103 Bcl1 cells (100 μl) were injected into the recipient mice via 
the tail vein 4 hours before the transfer of TCD bone marrow cells and splenic T cells for 
aGvHD induction (Figure 7). 
 





Figure 7. Experimental schematic of the combined aGvHD/GvL mouse model 
 
2.2.3.1.3 Long-term treatment  
After the induction of the combined aGvHD/GvL mouse model (day 0), the recipient 
mice were treated intraperitoneally (i.p.) at day3, 4, 5, 7, 9, and 12 with either free 
betamethasone (10 mg/kg, BMZ) or BMP-NPs (10 mg/kg, IOH-NPs, containing 
betamethasone phosphate) at equivalent dose of the drug. Mice treated with the same 
volume of PBS or the same volume of EP-NPs (empty IOH-NPs without the drug) served 
as a control to BMZ or BMP-NPs, respectively (Figure 8). 
 
 
Figure 8. Scheme of the long-term treatment of the aGvHD/GvL mouse model 
2.2.3.2 Assessment of disease progression in the aGvHD/GvL mouse model 
2.2.3.2.1 Assessment of the severity of aGvHD 
The BALB/c recipient mice were scored for the disease from day 2 to 40 (Figure 8) 
based on the aGvHD clinical scoring system and sacrificed for ethical reasons as 




described before (2.2.2.2). Mice were euthanized at day 40 if no severe aGvHD 
symptoms or no Bcl1 lymphoma features were observed. 
 
2.2.3.2.2 Assessment of Bcl1 lymphoma progression 
The development of the adoptively transferred Bcl1 lymphoma in the recipient mice was 
determined by daily flow cytometric analysis of the percentage of Igλ+ cells in peripheral 
blood starting at day 15. Mice were sacrificed if the percentage of Bcl1 cells exceeded 50 % 
of all lymphocytes in the peripheral blood. Mice were euthanized at day 40 if no severe 
aGvHD symptoms or no Bcl1 lymphoma features were observed. 
 
2.2.3.3 Flow cytometric analysis of Bcl1 lymphoma cells 
Peripheral blood of the mice was collected from the tail tip (5-6 drops/mouse) starting 15 
days after the induction of the combined aGvHD/GvL mouse model. FACS tubes were 
filled with Alsevers solution for the preservation of blood samples. The samples were 
centrifuged at 350 × g, 5 min at RT, the supernatant was discarded, and next washed with 
4 ml FACS buffer. The samples were centrifuged again and the supernatant was removed. 
The cells were stained with the monoclonal fluorochrome-conjugated antibody: anti-Igλ 
light chain (1:50,000 dilution) at 4 °C in the dark for 20 min. Then the cells were washed 
with FACS buffer and the supernatant was removed completely; 100 μl OptiLyse B lysis 
buffer was added to each sample, and incubated for 12 min at RT in dark. Then 1ml 
H2Odest was added to the samples, and incubated for 1 - 2 hours at RT in dark. The cells 
were washed with 3 ml FACS buffer, centrifuged, the supernatant removed, and used for 









Figure 9. Gating strategy of the flow cytometric analysis of Bcl1 lymphoma cells in the 
blood. Bcl1 lymphoma cells in peripheral blood were stained with a PE-conjugated anti-Igλ 
antibody and their percentage was analyzed by FACS. 
 
2.2.4 Phenotypic analysis of donor T cells 
2.2.4.1 Purification of donor T cells 
T cells were magnetically purified from individual GRflox and GRlck mice according to the 
protocol described before (2.2.2.1.3).  
2.2.4.2 FACS staining of T cells 
1 × 106 purified T cells from each mouse were stained with monoclonal antibodies 
conjugated with different fluorochromes, used for flow cytometry analysis and the data 
were analyzed with FlowJo software. 
2.2.4.2.1 Extracellular staining 
The cells were stained in FACS tubes with pre-diluted antibodies: anti-CD4, anti-CD8, 
anti-CD25, anti-CD44, anti-CD62L, anti-CD49d, anti-CD11a and anti-CXCR3 for 20 
min at 4 ˚C in dark. Next, the cells were washed with 3 ml FACS Buffer, centrifuged for 
5 min at 300 × g. The supernatant was discarded; the pellet was resuspended, and used 
for FACS analysis. 
 




2.2.4.2.2 FoxP3 intracellular staining 
The purified T cells were first stained extracellularly with anti-CD4 and anti-CD25 
antibodies. Then, a FoxP3 intracellular staining was conducted using the FoxP3 Staining 
Buffer Set following the manufacturer’s protocol. In brief, the Fix/Perm Buffer was 
prepared by diluting the Fix/Perm Concentrate with the Fix/Perm Diluent at a ratio of 1:4, 
and the Perm-Buffer was prepared by diluting the 10 × Perm Buffer with H2Odest (1:10 
dilution). 300 µl of Fix/Perm Buffer were added to each sample. The cells were incubated 
for 30 min at RT in dark, centrifuged, washed with 2 ml PBS, and followed by washing 
with 1 ml Perm-Buffer. Next, 200 µl Perm-Buffer and 20 µl anti-FoxP3 were added to 
each sample, vortexed and incubated for 30 min at 4 ˚C. Thereafter, the cells were 
washed with 1 ml Perm-Buffer, centrifuged, and washed with 3 ml FACS Buffer. Finally, 
the supernatant was discarded and used for FACS analysis. 
 
2.2.5 Fluidigm® gene chip analysis 
2.2.5.1 Preamplification of cDNA using TaqMan PreAmp Master Mix 
The cDNA was synthesized from 1 μg total RNA isolated from tissues described above. 
The cDNA samples were then diluted with DNA Suspension Buffer (10 mM Tris, pH 8.0, 
0.1 mM EDTA) at a concentration corresponding to 8 ng/μl of total RNA transcribed into 
cDNA.  
The pooled STA (Specific Target Amplification) master mix was prepared by adding 1 μl 
of 100 μM of each primer pair (up to a total of 96 primer pairs) to DNA Suspension 
Buffer to reach a final volume of 200 μl. 
Subsequently, the Pre-mix was prepared (Table 10) and 3.75 μl were added to each tube 
(8-well strip Micro PCR tube). Then, 1.25 μl pre-diluted cDNA were added, resulting in a 
total volume of 5 μl. The tubes were vortexed and centrifuged. 
 




Table 10. Preamplification sample Pre-mix 
Component Volume/ 
Reaction (μl) 
Volume for 48 
Reactions 
w/Overage (μl) 
Volume for 96 
Reactions 
w/Overage (μl) 
Pre-mix TaqMan PreAmp 
Master Mix 
2.5 132 264 
Pooled STA 
Master Mix 
0.5 26.4 52.8 
DNA Suspension 
Buffer 
0.75 39.6 79.2 
cDNA (μl) 1.25 
Total volume (μl) 5 
 
The tubes were placed in the ThermoCycler using the following PCR program. 
 
Step Temperature (ºC) Time Cycles 
Hold 95 10 min 1 
Denaturation 95 15 sec 
14 
Annealing/elongation 60 4 min 
Hold 4 ∞ 
 
After the preamplification, unincorporated primers were removed by performing the 














DNase-free water 1.4 84 168 
Exonuclease I Reaction 
Buffer 
0.2 12 24 
Exonuclease I (20 U/ μl) 0.4 24 48 
Total (μl) 2 120 240 
 
2 μl of the above Master mix was added to each tube, then the tubes were vortexed, 
centrifuged and placed in the ThermoCycler, using the PCR program listed below. 
Cycles Temperature (ºC) Time 
Digestion 37 30 min 
Inactivation 80 15 min 
Hold 4 ∞ 
 
The products were diluted 5-fold by adding 18 μl DNA Suspension Buffer to the final 
volume of 25 μl. The diluted reactions were stored at -20 ºC for further use. 
2.2.5.2 Preparing Sample Pre-Mix and samples 
The Sample Pre-Mix was prepared and 3.3 μl of it was added to each well of a 96-well 
plate. Next, 2.7 μl of preamplified and Exonuclease I-treated samples were added to the 
individual wells. The plate was vortexed thoroughly and centrifuged. The component of 













Volume for 48.48 




2 × SsoFast 
EvaGreen Supermix 
with low ROX 
2.5 3 180 
20 × DNA Binding 
Dye 
0.25 0.3 18 
PreAmp and Exo I-treated sample 2.25 2.7 - 
Total Volume (μl) 5 6 - 
 
2.2.5.3 Preparing the Assay Mix 
The individual specific forward (100 μM) and reverse (100 μM) primers were combined 
and 0.6 μl of the combined primers were added to each well of a 96-well plate. 5.4 μl of 
the Assay Mix were added to each well and the plate was vortexed, centrifuged before 
pipetting the assays into the Integrated Fluidic Circuit (IFC) inlets. The component of the 
Assay Mix is shown below: 
 
Component Volume per inlet 
(μl) 
Volume per inlet 
with overage (μl) 
Assay mix 2 × Assay Loading 
Reagent 
2.5 3 
1 × DNA Suspension 
Buffer 
2 2.4 
Combined forward and reverse primers 
(50 μM ) 
0.5 0.6 
Total (μl)* 5 6 
* The final concentration of each primer is 5 μM in the inlet and 500 nM in the final reaction 




2.2.5.4 Priming and loading the Dynamic Array IFC 
To prime the 48.48 IFC, the control line fluid was injected into each accumulator on the 
IFC. The film on the bottom of the IFC was removed subsequently. Next, the IFC was 
placed in an integrated fluidic circuit Controller MX (for 48.48 Dynamic Array), and the 
program: Prime (113×) was used. After the priming step, 5 μl of each assay and 5 μl of 
each sample were loaded in the respective inlets. Then, the IFC was returned to the IFC 
Controller MX for loading the chip and the load script: Load Mix (113×) was run. Any 
dust particles or debris were removed from the IFC surface using a Scotch Tape. The chip 
was run with the Biomark Gene expression Data Collection software. Parameters 
required by the set-up of the Biomark were selected and double-checked, and the 
“thermal protocol: GE 48 × 48 PCR + Melt v2.pcl” was used. The Table Results and 
Heat Map were imported; the data were analyzed using the ∆∆Ct method, and normalized 
to the house-keeping gene (Hprt). 
 
2.2.6 Real-time quantitative PCR 
2.2.6.1 Total RNA isolation 
Mice were sacrificed by CO2 inhalation; the organ biopsies were collected, frozen in dry 
ice and stored at -80 ºC for further analysis. 
RNA extraction was performed using the Qiagen RNeasy® Plus Universal Kit according 
to the manufacturer’s protocol. The samples were added to 900 μl of QIAzol™ in 14 ml 
RNase-free tubes, and homogenized with the Tissue Homogenizer Ultra Turrax T18 
Basic. Then 100 μl of gDNA eliminator were added to each sample, and vigorously 
vortex for 15 s. 180 μl of chloroform were added to the samples, vortexed for 15 s and 
incubated at RT for 2-3 min. After incubation, the samples were centrifuged at 14,000 
rpm for 15 min at 4 ºC. The aqueous phase (roughly 600 μl) was transferred to new tubes, 
and the same volume of 70 % ethanol was added, mixed and subsequently transferred to 
RNeasy-Mini columns. In the next step, the columns were centrifuged at 14,000 rpm for 
20 s at RT. The supernatant was discarded and 700 μl RWT buffer were added to the 




columns, centrifuged at 10,000 rpm for 20 s at RT. The flow-through was discarded and 
500 μl of RPE buffer were added to the columns, centrifuged at 10,000 rpm for 2 min at 
RT. The columns were subsequently placed in new collection tubes, centrifuged at 
10,000 rpm for 1 min at RT for complete removal of residual liquid. Then the columns 
were washed twice with 35 μl RNase-free water by centrifugation of 10,000 rpm for 1 
min. The desired RNA was contained in the eluate. The RNA samples were stored at -80 
ºC and the concentration was measured using a Nanodrop device. Protein contamination 
was measured by its absorbance at 260 nm, and organic contamination was measured at a 
wavelength of 230 nm. The integrity of RNA was detected using a 1 % agarose gel 
electrophoresis containing ethidium bromide. RNA was considered intact if two bands of 
28 S and 18 S were visible under UV light. 
2.2.6.2 Complementary DNA (cDNA) reverse transcription 
An amount of 1 μg total RNA was transcribed into double-stranded cDNA using the 
iScript™ cDNA Synthesis Kit according to the manufacturer’s protocol. Briefly, 4 μl of 5 
× iScript Reaction Mix and 0.25 μl of iScript Reverse Transcriptase were added to each 
RNA sample, adjusted to a final volume of 20 μl with Nuclease-free water. The reverse 
transcription reaction was performed in a thermocycler: Priming for 5 min at 25 ºC; 
Reverse Transcription for 30 min at 42 ºC; Inactivation for 5 min at 85 ºC. 
2.2.6.3 Conventional polymerase chain reaction 
The integrity of transcribed cDNA was confirmed by conventional PCR via amplification 
of house-keeping gene hypoxanthine guanine phosphoribosyl transferase (Hprt) and 









Table 11. PCR reaction mix 
Reagent Volume (μl) 
dd H2O 12.7 
Phusion Reaction buffer HF 4 
Combined forward/reverse Hprt Primer (10 μM) 1 
dNTPs (5 mM) 1 
cDNA template 1 
PhuS (DNA polymerase) 0.3 
 
The PCR reaction was performed with a Thermocycler Mastercycler EP Gradient using 
the following reaction program: 
Step Temperature (ºC) Time Cycles 
Initialization 98.5 2 min 1 
Denaturation 98.5 20 s 
30 Annealing 64 15 s 
Elongation 72 20 s 
Final elongation 72 2 min 1 
 
5 μl of Orange G (loading buffer) were added to the PCR products and loaded on a 1 % 
agarose gel.  
2.2.6.4 Real-time quantitative PCR (RT-qPCR) 
A RT-qPCT was performed to analyze the relative expression of the target genes using 
the Applied Biosystems 7500 Real-Time PCR System. For each well, the reaction mix 
contained 12.5 μl SYBR green, 11 μl ddH2O, 0.5 μl primer mix and 1 μl of cDNA, 
loaded into a 96-well Optical Reaction Plate, and the plate was sealed with Bemis® 
Parafilm. The results were analyzed with the ∆∆Ct method and normalized to the house-
keeping gene (Hprt). 




2.2.7 Enzyme-linked Immunosorbent Assay 
Mice were sacrificed on day 4, 5 and 6, blood samples were harvested by heart puncture 
with a 24G needle, left in BD Microtainer SST tubes for coagulation for at least 30 min at 
RT, and centrifuged at 14000 × g for 2 min. The serum supernatant was collected after 
centrifugation and stored at -20 ºC for further analysis. 
The protein level of IFNγ, IL6 and TNFα were analyzed using commercial Enzyme 
Linked Immunosorbent Assay Kits based on the manufacturer’s protocol. In brief, Nunc-
Immuno™ MicroWell™ 96-well plates were coated with 100 μl coating buffer, sealed 
with Bemis® Parafilm and incubated overnight in dark at 4 °C. On the second day, the 
plates were washed 4 times with PBST, blocked with 200 μl Assay Diluent and incubated 
for 1 hour on a shaker at RT. Then the plates were washed 4 times. The serum samples 
and standards were diluted with Assay Diluent, and added to the appropriate wells. The 
plates were sealed and incubated at RT for 2 hours with shaking. After washing 4 times, 
100 μl Detection Antibody solution was added to each well, the plates were incubated on 
the shaker for 1 hour at RT. The plates were washed and 100 μl diluted Avidin-HRP 
solution were added to each well, and incubated for 30 min on a shaker. Afterward, the 
plates were washed 5 times, soaking for 30 seconds to 1 minute per wash. 100 μl of TMB 
Substrate Solution were added to each well, incubate in the dark for 15-30 min. In the end, 
100 μl Stop Solution were added to each well and the plates were read at 450 nm and 570 
nm within 15 min. 
 
2.2.8 Histology and Immunohistochemistry 
2.2.8.1 Preparation of biopsies 
The biopsies were harvested from mice on day 4, 5 and 6 after the induction of aGvHD. 
All biopsies of the small intestine were harvested from the central region of the jejunum. 
The undesired content of the jejunum was flushed out with 4 % PFA using a 24 G needle. 
Next, the biopsies were fixed with 4 % PFA for 48 hours at RT. After the fixation step, 
they were cut into three 1 cm pieces, wrapped in filter paper and transferred in histology 




cassettes. The samples were dehydrated and embedded in paraffin using the Tissue 
Processor Excelsior ES at the Institute of Pathology of the University Medical Center 
Göttingen (Dr. med. Hanibal Bohnenberger). The paraffin-embedded biopsies were 
sectioned at a thickness of 2 µm using a microtome. Then, hematoxylin and eosin (H&E) 
and CD3 stainings were performed according to the standard protocols at the Institute of 
Pathology of the UMG by Jennifer Appelhans from the group of Dr. Bohnenberger using 
the automatic system Tissue Tek Prisma Slide Stainer. 
2.2.8.2 Assessment of histological staining 
Histopathological scoring was performed based on H&E staining. Four parameters were 
assessed in ten fields per slide: 1) Villous blunting (0 = none. 1 = yes; 20 × 
magnification), 2) Number of apoptotic cells (40 × magnification), 3) Inflammation (0 = 
none, 1 = mild, 2 = moderate without abscess, 3 = presence of abscess, erosion or ulcer; 
20 × magnification), 4) Edema (0 = none, 1 = yes, 20 × magnification). The sum of all 
four parameters was used as the final histological score. 
The number of CD3+ T cells infiltrating to the small intestine was determined based on 
the immunohistochemical staining. It was counted with photomicrographs using a Zeiss 
Axio Scope A1 microscope at 20 × magnification. For each slide, 10 fields were captured, 
the number of stained T cells was counted, and the average was calculated. All scoring 
was performed blindly. 
 
2.2.9 RNA sequencing analysis 
Total RNA was isolated from the inflamed small intestines and used for RNAseq analysis. 
Poly(A) RNA was isolated with oligo d(T) beads, transcribed into cDNA, and sequencing 
libraries were prepared with the TruSeq RNA library Kit. Paired end 50 bp reads from 
Illumina sequencing were mapped against the mouse mm 9 reference genome with the 
Spliced Transcripts Alignment to a Reference (STAR) software. One outlier sample was 
removed based on principle component analysis (PCA). Counts were normalized for read 
depth and only genes with an average read above 100 were used for further analysis using 




the BioJupies package with default parameters. The RNAseq was performed and 
analyzed by Marina Borshiwer under the supervision of Dr. Sebastiaan Meijsing at the 
Max Planck Institute for Molecular Genetics in Berlin. 
 
2.2.10 Analysis of myeloid cell origin after HSCT in mice 
T-cell-depleted bone marrow cells and T cells were isolated from the CD45.1-congenic 
C57BL/6 mice and transplanted into CD45.2 BALB/c mice to induce aGvHD. On day 6 
after disease induction, the mice were sacrificed and spleen and small intestine were 
harvested. 
2.2.10.1 Preparation of splenocytes 
The spleens were processed into single cell suspensions by passing through a 40 µm cell 
strainer. Next, cells were washed with 40 ml PBS, centrifuged at 300 × g for 7 min at 4 
˚C, the supernatant was discarded and 4 ml of TAC Lysis Buffer were added to each 
sample. After incubation at RT for 12 min, the cells were washed with 20 ml PBS, 
centrifuged and the supernatant discarded. Finally, the splenocytes were resuspended in 1 
ml PBS and used for FACS staining. 
2.2.10.2 Isolation of lamina propria cells 
The small intestine was washed with cold PBS and the payer patches were removed, then, 
the small intestine was cut open longitudinally and placed in a 6-well plate filled with 
PBS + 60 mM EDTA + 3 mM DTT for 45 min on ice. Next, the samples were transferred 
to 50 ml tubes filled with 20 ml PBS and shacked vigorously for 1 min to remove the 
epithelial cells, the process was repeated twice and 10 ml of PBS was used for the last 
time. 5 ml RPMI++ media were added to the samples to eliminate EDTA, then the 
samples were cut into small pieces and digested with 4 mg collagenase type II, 4 mg 
collagenase type 1-A and recombinant 500 U DNase I. The digestion was performed at 
37 ˚C for 30 min, and the samples were vortexed every 10 min during the digestion. In 
the end, the samples were passed through a 40 µm cell strainer, centrifuged at 300 × g for 




10 min and resuspended with 400 µl PBS to obtain single cell suspensions. The cells 
were used for FACS analysis. 
2.2.10.3 Flow cytometry analysis 
The splenocytes were stained with fluorochrome-conjugated antibodies: anti-CD45.1 and 
anti-CD45.2, and the lamina propria cells were incubated with anti-mouse CD16/32 for 
20 min at 4 ˚C in dark, and then stained with anti-CD45.1, anti-CD45.2, and anti-CD11b 
monoclonal antibodies according to our standard protocol. The composition of donor-
derived or recipient-derived lymphocytes in spleen and the origin of myeloid cells in 
lamina propria were analyzed using FACS analysis. The gating strategy is depicted in 
Figure 16. 
 
2.2.11 Preparation of individual cell population from mice 
2.2.11.1 Preparation of T cells 
T cells were isolated from the spleens of C57BL/6 mice using the EasySep™ Negative 
Selection Mouse T Cell Isolation Kit as described above (2.2.2.1.3). 
2.2.11.2 Enrichment of peritoneal macrophages 
1 ml of thioglycolate was injected intraperitoneally into BALB/c mice to attract 
macrophages to the peritoneum. Four days post injection, the mice were sacrificed and a 
peritoneal lavage was performed. The peritoneal membrane was carefully cut open, and 2 
ml of PBS/BSA was injected into the peritoneum, then, it was washed by performing a 
gentle abdomen massage. The liquid in the peritoneum was collected, and the step was 
repeated twice. The cells were washed with PBS/BSA, centrifuged 350 × g, at 4 ˚C for 5 
min and the supernatant was discarded. 
 
 




2.2.11.3 Preparation of intestinal epithelial cells 
The small intestines were harvested from BALB/c mice, and they were processed with 
the same protocol as for the isolation of lamina propria cells (2.2.10.2), but this time 
epithelial cells were retained for further analysis after vigorous shaking. The supernatant 
after each shaking was passed through a 100 µm cell strainer to collect the epithelial cells. 
The samples were centrifuged at 300 × g for 10 min, and the supernatant was discarded. 
Next, the pellets were resuspended in 300 µl of EasySep™ Recommended Medium. The 
cell concentration was adjusted to 1 × 108 cells/ml and used for purification with the 
EasySep™ Mouse APC Positive Selection Kit based on the manufacturer’s protocol. The 
samples were placed in 5 ml FACS tubes, FcR blocker (10 µl/ml) and APC-conjugated 
CD326 antibody (1 µg/ml) were added to each sample, which was then incubated for 15 
min at RT. The samples were washed with a 10-fold of excess Recommended Medium, 
centrifuged and the supernatant was carefully removed with a pipette. The samples were 
then resuspended in the same initial volume. The Selection Cocktail (100 µl/ml) was 
added to the samples, incubated for 15 min at RT. After the incubation, RapidSpheres™ 
(50 µl/ml) was added and incubated at RT for 10 min. The Recommended Medium was 
added up to 2.5 ml per sample, mixed and the tubes were placed into the magnet and 
incubated at RT for 5 min. The supernatant was poured out and the isolated epithelial 
cells remained in the tubes. This step was repeated two more times and the desired cells 
were finally harvested from the tubes. 
Total RNA was extracted from T cells, peritoneal macrophages and intestinal epithelial 
cells, reverse transcribed into cDNA, and used for RT-qPCR analysis (2.2.6). 
 
2.2.12 51Chromium release assay 
2.2.12.1 Preparation of CD8+ T cells 
On day 6 after the aGvHD induction, CD8+ T cells were isolated from the spleens of 
recipient mice using the EasySep™ Mouse CD8+ T Cell Isolation Kit according to the 
manufacturer’s protocol. The single cell suspensions were obtained by passing the spleen 




through a 40 µm cell strainer. The cells were adjusted to a concentration of 1 × 108 cells/ 
ml, Rat Serum (50 µl/ml) and Isolation Cocktail (50 µl/ml) were added to the samples in 
FACS tubes, and incubated at RT for 10 min. Next, RapidSpheres™ (125 µl/ml) was 
vortexed, added to the samples, and incubated at RT for 5 min. Recommended Medium 
was then added to each sample up to 2.5 ml. The tubes were placed in the magnet, 
incubated at RT for 2.5 min, and the enriched CD8+ T cells were poured into Falcon 
tubes for further use. 
2.2.12.2 Cytotoxicity assay 
Bcl1 cells were freshly thawed and cultured in a 10 cm cell dish one day before the assay. 
Bcl1 cells were harvested and incubated with 
51Chromium at 37 °C for 1 hour. The 
labeled Bcl1 cells were subsequently transferred into a 96-well plate, and incubated in the 
presence of purified CD8+ T cells from aGvHD mice at 37 °C for 4 hour. Next, 5 µl of 10% 
Triton was added to the cells to lyse the cells and release all the chromium. The 
supernatant from each well was transferred to an absorbent plate. The plate was sealed 
and the radioactivity was measured using a specific formula. This part of the experiment 
was performed by Leslie Elsner from the group of Prof. Dr. Ralf Dressel. 
 
2.2.13 Statistical analysis 
Statistical analysis was done with GraphPad Prism 5 software. The results of gene 
expression were analyzed by two-tailed unpaired Student’s t-test. A one-way ANOVA 
followed by a Newman-Keuls multiple comparison test was used for clinical score 
analysis. The plots of qPCR and histological score were analyzed using Student’s t-test. 
A Log-rank Mantel-Cox test was performed to analyze the survival curve of aGvHD/GvL 
mouse model and a Kruskal-Wallis test followed by Dunn’s Multiple Comparison test 
was used for the analysis of lymphomagenesis. Data are presented as mean + standard 
error and considered significant if p-value was ≤ 0.05, the significance was depicted as: 






3.1 Transplantation of GC-resistant allogeneic T cells as well as GC-resistant 
myeloid cells into recipients both aggravate aGvHD in mice 
Allogeneic T cells are thought to be the main cause of aGvHD (Perkey and Maillard, 
2018). In addition, targeting recipient APCs that are largely composed of myeloid cells 
was also found to be a promising therapeutic intervention to aGvHD (Shlomchik, 1999). 
Besides, macrophages in the host are the cell population that is most resistant against 
irradiation during HSCT (Haniffa et al., 2009). Previously, it was shown in our group that 
GR-deficient allogeneic T cells transferred into recipient mice resulted in a more 
aggressive aGvHD in comparison to the transfer of wild type allogeneic T cells, which 
highlighted the importance of endogenous GCs in the modulation of aGvHD (Theiss-
Suennemann et al., 2015). More specifically, suppression of the function of CD8+ T cells 
was necessary to control aGvHD by endogenous GCs in this model. To confirm the 
contribution of GC-resistant (GRlck) allogeneic T cells to aGvHD, we transferred 2 × 106 
T cells from GRlck mice or GRflox mice as a control in combination with 1 × 107 T cell-
depleted (TCD) bone marrow cells purified from C57BL/6 mice into lethally irradiated 
BALB/c mice via tail vein injection to induce murine aGvHD as outlined in Figure 5. 
During the development of aGvHD, we scored the mice from day 2 to 6 based on five 
clinical parameters. We found that mice transferred with GC-resistant (GRlck) or GC-
responsive (GRflox) T cells both developed aGvHD while those mice only receiving bone 
marrow cells did not (Figure 10A). The disease especially exaggerated between day 5 
and 6. Moreover, mice transplanted with GRlck T cells suffered from a more severe 
aGvHD on day 6 after disease induction than mice receiving GRflox T cells (Figure 10B). 
To additionally assess the impact of endogenous GCs on recipient myeloid cells, we 
induced aGvHD by transplanting wild type allogeneic T cells isolated from C57BL/6 
mice into GRlysM mice or as a control into GRflox BALB/c mice (Figure 5). It is 
noteworthy that myeloid cells in GRlysM mice are GC-resistant. On day 6 after 
transplantation, GRlysM and GRflox mice both developed aGvHD, and the disease was 









Figure 10. Clinical scores of mice suffering from aGvHD after HSCT. Allogeneic T cells 
were magnetically purified from C57BL/6 mice and injected into the tail vein of BALB/c mice in 
combination with TCD bone marrow cells to induce aGvHD, and the transfer of only bone 
marrow cells (BMonly) served as a control. (A) Recipient mice were transferred with either GC-
resistant (GRlck) or GC-responsive (GRflox) T cells and were scored from day 2 to 6 based on five 
parameters: activity, posture, fur texture, diarrhea, and weight loss. N=4/9/7 (BMonly/ GRflox/ 
GRlck). (B) Clinical score on day 6 of individual mice injected with GC-resistant (GRlck) or GC-
responsive (GRflox) T cells. Date refer to the same experiment as in panel A. (C) Wild type 
allogeneic T cells were transferred into recipient mice with GC-resistant (GRlysM) or GC-
responsive (GRflox) myeloid cells to induce aGvHD and the clinical score was determined on day 
6. N=4/9/9 (BMonly/ GRflox/ GRlysM). Statistical analysis was performed using One-way ANOVA 
followed by a Newman-Keuls Multiple Comparison Test (*** p<0.001; n.s., not significant) (Li 







3.2 GC-resistance does not alter the phenotypes of the transferred allogeneic T cells 
To study the impact of endogenous GCs on allogeneic donor T cells in the context of 
aGvHD in mice, we took advantage of cell type-specific GR-deficient mice, namely 
GRlck mice in which the GR is deleted in the entire T cell lineage (Theiss-Suennemann et 
al., 2015). Since aGvHD is mainly driven by allogeneic T cells, and as the difference on 
the composition of the transplanted T cells might impact the pathogenesis of aGvHD in 
mice, immunological features including T cell subset frequencies, the activation 
condition of T cells, and the expression level of adhesion molecules and chemokine 
receptors on the cell surface were analyzed in both genotypes. To this end, we performed 
a flow cytometric analysis to compare the phenotype of GC-resistant (GRlck) and GC-
responsive (GRflox) T cells. 
3.2.1 Lack of the GR in T cells has no impact on cell frequencies  
In order to investigate the frequencies of individual subsets amongst the transferred T 
cells, we purified them from GRlck and GRflox C57BL/6 mice by magnetic negative 
selection. Then, the cells were stained with specific fluorochrome-labelled monoclonal 
antibodies. The FACS gating strategies used to determine CD4+, CD8+ and regulatory 
(Treg) T cells are depicted in Figure 11A and B. No significant differences were found in 
the percentages of these T cell subtypes between GRlck and GRflox mice (Figure 11C) and 









Figure 11. Percentages of CD4+, and CD8+ T cells as well as Treg cells amongst the GC-
resistant and GC-responsive T cells used for transplantation. T cells were magnetically 
purified from GRlck and GRflox C57BL/6 mice and stained with fluorochrome-conjugated 
antibodies: CD4+ T cells (CD4-PercP), CD8+ T cell (CD8-APC), Treg (CD4-PercP, CD25-APC-
Cy7, and FoxP3-APC). The stained cells were subsequently used for cytometric analysis. (A) 
Gating strategy for CD4+ and CD8+ T cells. (B) Gating strategy for Treg cells. (C) Frequencies of 
T cell subsets amongst GC-resistant and GC-responsive T cells. (D) Ratio of CD4+/CD8+ T cells 
amongst GC-resistant and GC-responsive T cells. N= 5/3 (GRflox/GRlck). Statistical analysis was 
done using unpaired Student’s t-test, n.s.: not significant; (Li et al., 2019). 
 
3.2.2 GC-resistant T cells show a comparable activation level as GC-responsive T 
cells 
We additionally stained the isolated T cells from GRlck and GRflox C57BL/6 mice with 
anti-CD44 and anti-CD62L antibodies to determine their activation state (Figure 12A). 
GC-resistant CD4+ T cells showed the same level of activation as GC-responsive CD4+ T 
cells, while CD8+ T cells from GRlck mice were slightly more activated in comparison to 






Figure 12. Activation state of GC-resistant and GC-responsive T cells. T cells were 
magnetically purified from GRlck and GRflox C57BL/6 mice, and stained with fluorochrome-
conjugated antibodies: PercP-CD4, APC-CD8, PE-CD44 and APC-Cy7-CD62L. The stained 
cells were subsequently used for flow cytometric analysis. (A) Activated T cells were gated as 
CD44+CD62L- cells in all four experimental groups. (B) Percentages of CD44+CD62L- cells 
amongst CD4+ T cells and CD8+ T cells. N= 5/3 (GRflox/GRlck). Statistical analysis was done 
using unpaired Student’s t-test, n.s.: not significant; (Li et al., 2019). 
 
3.2.3 GC-resistant and GC-responsive T cells show similar levels of adhesion 
molecules and chemokine receptors on the cell surface 
To test the surface expression level of integrins and chemokine receptors on the 
transplanted T cells, we stained CD4+ and CD8+ T cells with fluorochrome-conjugated 
antibodies against CD11a (subunit of LFA-1), CD49d (subunit of VLA-4), and the 
chemokine receptor CXCR3 (Figure 13A). The surface levels of the adhesion molecules 
CD11a and CD49d as well as the chemokine receptor CXCR3 did not significantly differ 
between GC-resistant and GC-responsive T cells (Figure 13B). 
In conclusion, GR-deficiency in T cells neither impacts the phenotypes nor the activation 
state of the transplanted T cells. Therefore, GC-resistant T cells have similar phenotypic 







Figure 13. Expression levels of adhesion molecules and chemokine receptors on the surface 
of GC-resistant and GC-responsive T cells. T cells were magnetically purified from GRlck and 
GRflox C57BL/6 mice, and stained with fluorochrome-conjugated antibodies: CD4-PercP, CD8-
APC or CD8-PE-Cy7, CD11a-PE-Cy7 and CD49d-FITC or CXCR3-APC. The stained cells were 
subsequently used for flow cytometric analysis. (A) Gating strategies for the analysis of LFA-1, 
VLA-1, and CXCR3. (B) Mean fluorescence intensity of CD11a, CD49d, and CXCR3 on CD4+ 
or CD8+ T cells. N= 5/3 (GRflox/GRlck). Statistical analysis was done using unpaired Student’s t-
test, n.s.: not significant; (Li et al., 2019). 
 
3.3 Transplantation of allogeneic GC-resistant T cells results in increased systemic 
cytokine level and an up-regulation of disease-associated genes in aGvHD target 
organs 
During the development of aGvHD, pro-inflammatory cytokines such as IFN-γ and IL-6 
secreted by T cells, APCs and even non-hematopoietic cells, make an essential 
contribution (Baake et al., 2018). To test the production of cytokines, we induced aGvHD 
by infusing GC-resistant (GRlck) and GC-responsive (GRflox) T cells into lethally 
irradiated mice and sacrificed them on day 6 after disease induction. The blood was 





of allogeneic T cells led to an increased production of IFN-γ and IL-6, compared to the 
transplantation of only bone marrow cells. Moreover, the serum protein levels of these 
two cytokines were significantly higher in mice transplanted with GC-resistant T cells 
compared to those transferred with GC-responsive T cells (Figure 14), suggesting that 
mice receiving GC-resistant T cells experience a more severe aGvHD partially due to the 




Figure 14. Serum protein levels of IFN-γ and IL-6 in the blood of mice suffering from 
aGvHD. The lethally irradiated BALB/c mice were transferred with GC-resistant (GRlck) or GC-
responsive (GRflox) T cells in combination with TCD bone marrow cells purified from C57BL/6 
mice. Mice were sacrificed on day 6 after disease induction and the blood was collected via heart 
puncture. The protein levels of IFN-γ and IL-6 were measured by ELISA. N=5/9/10 












Figure 15. Gene expression of 
IFN-γ, Perf-1, GzmB, and IL-17 
in spleen, liver and small 
intestine of mice suffering from 
aGvHD induced by transfer of 
GC-resistant T cells. Lethally 
irradiated BALB/c mice were 
transferred with GC-resistant 
(GRlck) or GC-responsive (GRflox) 
T cells in combination with TCD 
bone marrow cells purified from 
C57BL/6 mice. Mice were 
sacrificed on day6 after disease 
induction. RNA was isolated from 
the spleen, liver and small 
intestine, and transcribed into 
cDNA. The cDNA was used for 
RT-qPCR analysis. Relative 
mRNA levels of IFN-γ, Perf-1, 
GzmB, and IL-17 were analyzed in 
spleen (A), liver (B), and small 
intestine (C) after normalization to 
the house-keeping gene Hprt. 
N=4/9/8 (BMonly/GRflox/GRlck). 
Statistical analysis was performed 
by unpaired Student’s t-test, *, p < 






To detect the impact of GR-deficiency in T cells on gene transcription, we isolated RNA 
from the two aGvHD target organs liver and small intestine and from the secondary 
lymphoid organ spleen, transcribed it into cDNA and analyzed the relative expression of 
four genes. In the spleen, IFN-γ, Perf-1, GzmB, and IL-17 were up-regulated in aGvHD 
mice; the expression of IFN-γ, Perf-1, and IL-17 were significantly more increased in 
mice receiving GC-resistant T cells in comparison to those receiving GC-responsive T 
cells, and GzmB was also further up-regulated in mice transplanted with GRlck T cells but 
this was not significant (Figure 15A). In the liver, only two genes, IFN-γ and Perf-1 were 
found to be significantly increased in mice transplanted with GC-resistant T cells, 
compared to those ones transferred with GC-responsive T cells (Figure 15B). In contrast, 
transcriptional levels of all four genes were significantly increased in the small intestine 
of mice receiving GRlck T cells (Figure 15C). Collectively, our data suggest that mice 
transplanted with GC-resistant T cells suffer from a more severe aGvHD, and show an 
increased production of pro-inflammatory cytokines at both the protein and mRNA level. 
Expression analysis of the small intestine indicates that key genes of aGvHD in this target 
organ are altered in mice, for which reason biopsies of the inflamed small intestine were 
prepared for further gene expression analysis. 
 
3.4 GC-resistance of allogeneic T cells but not myeloid cells alters the gene 
expression profile in the inflamed small intestine in mice undergoing aGvHD 
The pathogenesis of aGvHD in mice can be subdivided into several phases as outlined 
earlier: priming of APCs, activation, proliferation and migration of donor allogeneic T 
cells, and the effector phase of activated donor T cells in the target organs (Ferrara et al., 
2009). During the development of aGvHD, various cytokines, chemokines, and 
chemokine receptors play a critical role, and allogeneic donor T cells are considered as 
the main contributor to aGvHD. Furthermore, T cells undergo a series of metabolic 
changes upon being activated, to meet dramatic needs for ATP production and metabolic 
intermediates required by biomass synthesis and the shift from oxidative phosphorylation 





Therefore, metabolism related enzymes, transporters, and regulators of the metabolic 
switch involved in autoimmune disorders and T-cell metabolism were suggested as 
targets for therapeutic intervention (MacIver et al., 2013; O’Sullivan and Pearce, 2015). 
To identify genes that were differentially regulated when allogenic T cells were GC-
resistant, we checked the literature and selected 54 genes that we considered to be related 
to the immunosuppressive functions of GCs in the context of mouse aGvHD. These 
selected genes were categorized into five groups: category 1 and 2 contained cytokines 
and chemokines, respectively (Table 12); category 3 included cell surface molecules 
involved in cell adhesion, co-stimulation, apoptosis induction and pathogen-recognition; 
category 4 encompassed intracellular proteins mostly with enzymatic activity (Table 13), 
and the final category 5 consisted of genes linked to cellular energy metabolism and 
nutrient transport (Table 14).  
We induced aGvHD using GC-resistant allogeneic T cells (GRlck), recipient mice 
harboring GC-resistant myeloid cells (GRlysM), or the respective controls, and sacrificed 
mice on day 6 after disease induction. The inflamed small intestines were collected and 
used for RNA isolation. The expression levels of the 54 selected genes were determined 
by Fluidigm® gene chip analysis. In the first category related to cytokines, the majority of 
the selected genes, Csf2, Il4, Il2, Il1b, Il10, Il12, and Il6, were significantly up-regulated 
in mice receiving GC-resistant allogeneic T cells (GRlck), relative to mice receiving wild 
type GC-responsive allogeneic T cells (GRflox). The results are depicted as the fold 
change between both groups on day 6 after aGvHD induction. In contrast, no differences 
were found concerning the expression profile of any of the selected genes between 
GRlysM and wild type GRflox recipient mice transferred with wild type T cells (Table 12). 
In the second group, all the selected genes associated with chemokines (Ccl5, Cxcl9, 
Cxcl11, Cxcl10, Ccl3, Ccl7, Ccl2, Cxcl5, Cxcl13, and Cxcl1) were transcriptionally 
increased in mice transferred with GRlck T cells compared to those ones receiving GRflox 
T cells on day 6 after disease induction. Similar to the category 1, the expression profile 
of these chemokine-related genes was unaltered between mice harboring GRlysM and 





  GRlck vs. GRflox 
at day 6 
 GRlysM vs. GRflox 





 Fold change Unpaired 
t-test 
 Fold change Unpaired t-
test 




    
TNFα Tnf 1.6 n.s.  0.8 n.s. 
M-CSF Csf1 1.6 n.s.  1.0 n.s. 
IL-33 Il33 1.7 n.s.  1.6 n.s. 
GM-CSF Csf2 2.1 *  1.2 n.s. 
IL-4 Il4 2.5 **  0.8 n.s. 
IL-2 Il2 2.6 ***  1.2 n.s. 
IL-1β Il1b 2.8 *  1.1 n.s. 
IL-10 Il10 2.9 *  1.2 n.s. 
IL-12 Il12 3.5 ***  1.2 n.s. 
IL-6 Il6 13.7 *  1.0 n.s. 
       
CCL5 Ccl5 1.7 *  1.1 n.s. 
CXCL9 Cxcl9 2.2 *  1.2 n.s. 
CXCL11 Cxcl11 2.4 **  1.2 n.s. 
CXCL10 Cxcl10 3.1 **  1.2 n.s. 
CCL3 Ccl3 3.6 **  1.1 n.s. 
CCL7 Ccl7 5.1 **  1.3 n.s. 
CCL2 Ccl2 5.3 *  1.0 n.s. 
CXCL5 Cxcl5 5.9 **  1.1 n.s. 
CXCL13 Cxcl13 6.1 **  1.6 n.s. 
CXCL1 Cxcl1 6.4 *  1.2 n.s. 
 
Table 12. Expression analysis of cytokine and chemokine genes potentially important in the 
context of murine aGvHD. Two mouse aGvHD models were either induced by transferring GC-
resistant (GRlck) or GC-responsive (GRflox) T cells isolated from C57BL/6 mice into lethally 
irradiated wild type BALB/c mice, or by transferring wild type C57BL/6 allogeneic T cells into 
GRlysM (with GC-resistant myeloid cells) or GRflox BALB/c mice (with GC-responsive myeloid 
cells). On day 6 after disease induction, RNA was isolated from the inflamed small intestines, 
transcribed into cDNA, and subsequently used for high-throughput qPCR analysis. The upper part 
of the table represents the category of cytokines; the lower part represents the category of 
chemokines. The data are presented as fold-change with a different color code, yellow for no 
changes, light green for ≤ 3-fold, and dark green for > 3-fold changes. N=9/10 (GRflox / GRlck) and 
N=8/9 (GRflox / GRlysM). Statistical analysis was performed using unpaired Student’s t-test, *, p < 






In the third group of genes related to cell surface molecules, the transcriptional levels of 
many of them (Cd14, Klrk1, Cd28, Itgb2, Fasl, Chil3, and Ctla4) were increased in mice 
transplanted with GC-resistant T cells (GRlck), in comparison to those transferred with 
GC-responsive T cells (GRflox). However, in GRlysM mice receiving wild type allogeneic 
T cells, only two genes were transcriptionally altered (Itgam was down-regulated and 
Cd14 was up-regulated), compared to GRflox recipient mice (Table 13). In the fourth 
category, three genes (Ptgs2, Dusp1, and Arg1) were significantly up-regulated in mice 
transplanted with GC-resistant T cells and only one gene Ptgs2 was increased on the 
transcriptional level in recipient mice with GC-resistant myeloid cells (GRlysM), relative 
to their controls with GC-responsive myeloid cells (GRflox) (Table 13). 
  GRlck vs. GRflox 
at day 6 
 GRlysM vs. GRflox 





 Fold change Unpaired 
t-test 
 Fold change Unpaired 
t-test 




    
MHC II H2-Aa 1.0 n.s.  0.9 n.s. 
CD11a Itgal 1.5 n.s.  1.7 n.s. 
CD11b Itgam 1.8 n.s.  0.45 * 
TLR4 Tlr4 2.1 n.s.  1.6 n.s. 
CD14 Cd14 2.2 *  1.8 ** 
NKG2D Klrk1 2.2 *  1.2 n.s. 
CD28 Cd28 2.6 *  1.1 n.s. 
CD18 Itgb2 2.6 **  1.2 n.s. 
CD95L Fasl 3.6 **  1.0 n.s. 
YM1 Chil3 5.3 *  0.9 n.s. 
CTLA4 Ctla4 5.6 **  1.1 n.s. 
       
ERK2 Mapk1 1.1 n.s.  0.8 n.s. 
NOX2 Cybb 1.2 n.s.  1.5 n.s. 
GILZ Tsc22d3 1.3 n.s.  1.0 n.s. 
COX2  Ptgs2 1.6 *  1.4 * 
iNOS Nos2 1.8 n.s.  1.3 n.s. 
DUSP1 Dusp1 3.9 **  1.3 n.s. 
ARG1 Arg1 





Table 13. Expression analysis of genes related to cell surface molecules and intracellular 
proteins in the context of murine aGvHD. Two mouse aGvHD models were either induced by 
transferring GC-resistant (GRlck) or GC-responsive (GRflox) T cells isolated from C57BL/6 mice 
into lethally irradiated wild type BALB/c mice, or by transferring wild type C57BL/6 allogeneic 
T cells into GRlysM (with GC-resistant myeloid cells) or GRflox BALB/c mice (with GC-responsive 
myeloid cells). On day 6 after disease induction, RNA was isolated from the inflamed small 
intestines, transcribed into cDNA, and subsequently used for high-throughput qPCR analysis. The 
upper part of the table represents the category of cell surface molecules; the lower part represents 
the category of intracellular proteins. The data are presented as fold-change with a different color 
code, yellow for no changes, light green for ≤ 3-fold, dark green for > 3-fold, and light blue ≥ 0.3-
fold changes. N=9/10 (GRflox / GRlck) and N=8/9 (GRflox / GRlysM). Statistical analysis was 
performed using unpaired Student’s t-test, *, p < 0.05; **, p < 0.01; n.s., not significant; (Li et al., 
2019). 
 
In the fifth category, we analyzed the expression of genes relevant for metabolic 
reprogramming of T cells. Amongst the selected genes, only three (Hk2, Hif1a, Slc2a1) 
were significantly up-regulated in mice receiving GC-resistant T cells (GRlck), and no 
genes were found to be altered between GRlysM and GRflox mice transplanted with wild 
type allogeneic T cells (Table 14). 
  GRlck vs. GRflox 
at day 6 
 GRlysM vs. GRflox 





 Fold change Unpaired 
t-test 
 Fold change Unpaired 
t-test 




    
PGC-1 Ppargc1a 0.6 n.s.  0.9 n.s. 
Estrogen-related receptor  Esrra 0.7 n.s.  0.9 n.s. 
HMG-CoA reductase Hmgcr 0.8 n.s.  0.9 n.s. 
Carnitine palmitoyltransferase 1A Cpt1a 0.9 n.s.  1.0 n.s. 
Phosphofructokinase, liver type Pfkl 0.9 n.s.  1.1 n.s. 
Slc7a5 / LAT1 Slc7a5 1.0 n.s.  1.0 n.s. 
mTOR Mtor 1.0 n.s.  0.9 n.s. 
Pyruvate dehydrogenase E1 1 Pdha1 1.1 n.s.  1.1 n.s. 
Aldolase A Aldoa 1.1 n.s.  1.1 n.s. 
Acetyl-CoA carboxylase  Acaca 1.2 n.s.  1.2 n.s. 
c-Myc Myc 1.2 n.s.  1.3 n.s. 
Slc1a5 / ASCT2 Slc1a5 1.3 n.s.  1.4 n.s. 
AMP-activated protein kinase 1 Prkaa1 1.3 n.s.  1.1 n.s. 
Hexokinase 2 Hk2 2.0 *  1.1 n.s. 
Hypoxia-inducible factor 1 Hif1a 2.1 *  1.1 n.s. 





Table 14. Expression analysis of genes involved in metabolic changes in the context of 
murine aGvHD. Two mouse aGvHD models were either induced by transferring GC-resistant 
(GRlck) or GC-responsive (GRflox) T cells isolated from C57BL/6 mice into lethally irradiated 
wild type BALB/c mice, or by transferring wild type C57BL/6 allogeneic T cells into GRlysM 
(with GC-resistant myeloid cells) or GRflox BALB/c mice (with GC-responsive myeloid cells). On 
day 6 after disease induction, RNA was isolated from the inflamed small intestines, transcribed 
into cDNA, and subsequently used for high-throughput qPCR analysis. The data are presented as 
fold-change with a different color code, yellow for no changes, light green for ≤ 3-fold, and dark 
green for > 3-fold changes. N=9/10 (GRflox / GRlck) and N=8/9 (GRflox / GRlysM). Statistical 
analysis was performed using unpaired Student’s t-test, *, p < 0.05; n.s., not significant; (Li et al., 
2019). 
Taken together, our data on the gene expression profile highlight the importance of T 
cells as a major target of GC actions in the context of a mouse aGvHD. 
 
3.5 Myeloid cells in the inflamed small intestine are partially reconstituted in 
recipient mice after aGvHD induction 
In our gene expression profiling of 54 selected genes that are involved in potential effects 
of GCs on aGvHD, we found that the deficiency of the GR in myeloid cells of recipient 
mice (GRlysM) barely altered the expression levels of the selected genes (Table 12, 13, 
and 14). To explore the possible mechanisms, the origin of myeloid cells in recipient 
mice was analyzed. We conducted aGvHD induction by purifying allogeneic T cells and 
TCD-bone marrow cells from wild type C57BL/6 mice on a CD45.1 genetic background, 
and transferred them into BALB/c mice on a CD45.2 genetic background. Mice were 
sacrificed on day 6 after disease induction. Single-cell suspensions of splenocytes were 
obtained by passing them through a cell strainer, and lamina propria cells were isolated 
by enzymatic digestion as described in the Material and Method section.  
The origin of splenocytes as well as of myeloid cells in the inflamed small intestine was 
analyzed by flow cytometry. On day 6 after aGvHD induction, the majority of 
splenocytes in recipient mice were donor-derived, approximately 90% of splenocytes 
expressing the CD45.1 allele (Figure 17). However, around 75% of the myeloid cells that 
reside in the lamina propria of the inflamed small intestine were still derived from the 





proportion of approximately 25% (Figure 17). This indicates that myeloid cells in the 
small intestine are only partially reconstituted in recipient mice after TBI. 
 
Figure 16. Gating strategies used to determine the origin of splenocytes as well as myeloid 
cells in the small intestine of aGvHD mice. Murine aGvHD was induced by infusing wild type 
T cells in a combination with TCD bone marrow cells purified from C57BL/6 mice expressing 
the CD45.1 allele into lethally irradiated BALB/c mice expressing the CD45.2 allele via the tail 
vein. On day 6 after disease induction, the spleen and inflamed small intestine were removed 
from recipient mice. Splenocytes were obtained as single-cell suspensions and lamina propria 
cells were isolated from the small intestine by enzymatic digestion. (A) Splenocytes were stained 
using anti-CD45.1 and anti-CD45.2 fluorochrome-conjugated antibodies, and live cells were 
gated based on FSC and SSC. (B) Live cells in the lamina propria were identified using FSC and 
SSC, and an anti-CD11b antibody was used to define myeloid cells. The origin of myeloid cells 
was determined by anti-CD45.1 and anti-CD45.2 stainings. A representative example for each 






Figure 17. The origin of splenocytes as well as myeloid cells in the small intestine of aGvHD 
mice was determined by flow cytometric analysis. Murine aGvHD was induced by infusing 
wild type T cells in a combination with TCD bone marrow cells purified from C57BL/6 mice 
expressing the CD45.1 allele into lethally irradiated BALB/c mice expressing the CD45.2 allele 
by tail vein injection. On day 6 after disease induction, the spleen and small intestine were 
removed from recipient mice. Single-cell suspensions of splenocytes were produced and lamina 
propria cells were isolated from the small intestine. N=3. (A) Cell frequencies of donor-derived 
cells (CD45.1+) or recipient-derived cells (CD45.2+) in the spleen were analyzed by flow 
cytometry. (B) Percentages of donor-derived myeloid cells (CD11b+ CD45.1+) and recipient-
derived myeloid cells (CD11b+ CD45.2+) in the lamina propria of the small intestine were 
analyzed by flow cytometry; (Li et al., 2019). 
 
3.6 Identification of novel candidate genes in murine aGvHD triggered by GC-
resistant allogeneic T cells 
Our large-scale gene expression analysis showed that amongst the 54 selected genes, 
many were altered in mice transplanted with GC-resistant T cells, but the analyzed gene 
profile was limited to the categories that were already known to be regulated by GCs in 
inflammatory responses. To identify potential new candidate genes involved in the 
pathogenesis of aGvHD and regulated by GCs, we conducted an RNA-sequencing 
analysis to compare the transcriptome in the inflamed small intestine of mice transferred 
with GC-resistant (GRlck) or GC-responsive (GRflox) T cells. Total RNA was isolated 
from the inflamed small intestines, and used for sequencing analysis. When we carried 
out principle component analysis (PCA), we found that transplantation of GC-resistant 
allogeneic T cells profoundly affected the transcriptomic profile of the genes in the 





ArrayExpress Archive of Functional Genomics Data 
(https://www.ebi.ac.uk/arrayexpress/) with the accession number E-MTAB-7765. 
Bioinformatic analysis of RNA-sequencing data was performed using the BioJupies 
package with default parameters. An overview of the results can be accessed at the 








Figure 18. RNA-sequencing analysis of the inflamed small intestine in aGvHD mice 
transplanted with GC-resistant allogeneic T cells. RNA was extracted from the small intestines 
of mice receiving either GC-resistant (GRlck) or GC-responsive (GRflox) T cells on day 6 after 
disease induction and then used for RNA-sequencing analysis. (A) Three-dimensional principle 
component analysis (PCA) of 5 GRlck samples and 4 GRflox samples. (B) Gene ontology 
enrichment analysis of the up-regulated genes and the down-regulated genes, the top 10 profiles 
are depicted for each group. (C) Volcano plot of the differentially expressed genes, blue dots 
represent down-regulated genes, red dots represent up-regulated genes (adjusted p-value: -log10 P 
<0.05; fold change: log2FC >1.5). Selected genes for further expression analysis are indicated by 
arrows; (Li et al., 2019). 
The gene ontology enrichment analysis indicated that up-regulated and down-regulated 
genes were significantly enriched in inflammation-related and matrix disassembly 
profiles or the urea cycle and fatty acid oxidation profile, respectively (Figure 18B). 
Amongst the genes that were differentially expressed, 176 genes were significantly 
down-regulated and 370 genes were up-regulated in mice transplanted with GC-resistant 
T cells (Figure 18C). RNA-sequencing analysis was performed by Marina Borschiwer in 
the laboratory of Dr. Sebastiaan Meijsing. 
 
Table 15. Comparison of gene expression levels determined either by Fluidigm® gene chip 
analysis or RNA-sequencing. Murine aGvHD was induced by transplanting allogeneic GC-
resistant (GRlck) and GC-responsive (GRflox) T cells into lethally irradiated wild type BALB/c 
mice via the tail vein. RNA was isolated from the inflamed small intestines on day 6 after disease 
induction. Exemplary genes analyzed for the comparison of the two approaches of gene 
expression analysis, Fluidigm® gene chip analysis and RNA-sequencing, were selected from 
Tables 12-14. The data are presented as fold change in the color of dark green for > 3-fold. 
Statistical analysis was performed using unpaired Student’s t-test, *, p < 0.05; **, p < 0.01; ***, 





To assess the experimental consistency of the two approaches used for gene expression 
analysis, namely Fluidigm® gene chip analysis and RNA-sequencing, we compared the 
expression levels of a few genes selected from Tables 12-14. We found comparable 
results for the fold-change and the statistical significance of the expression levels of these 
genes, demonstrating similar results for the two distinct approaches (Table 15).  
 
3.7 Histological and immunohistochemical analyses indicate tissue damage and 
lymphocyte infiltration into the inflamed small intestine in aGvHD mice 
During the effector phase of aGvHD, infiltration of effector T cells into the small 
intestine results in massive tissue damage (Holtan et al., 2014). The clinical score curve 
showed that GRlck mice developed a more severe aGvHD than GRflox mice did, especially 
on day 6, the full-blown first phase of the disease (Figure 10A). Therefore, we intended 
to explore the possible mechanisms linked to the effector phase of aGvHD. To this end, 
we carried out a histological analysis to assess the tissue damage in the small intestine, a 
major target organ of aGvHD in mice. Furthermore, the infiltration of effector T cells into 
the small intestine was determined by immunohistochemical staining of CD3. Organ 
biopsies were harvested from mice receiving either GC-resistant (GRlck) or GC-







Figure 19. Histological and immunohistochemical analyses of the small intestines in mice 
suffering from aGvHD. The induction of aGvHD was performed by transferring GC-resistant 
(GRlck) or GC-responsive (GRflox) allogeneic C57BL/6 T cells into lethally irradiated BALB/c 
mice. Mice were sacrificed on day 4 or 6 after disease induction, and the small intestines were 
sectioned, dehydrated, embedded in paraffin, and subsequently processed for hematoxylin and 
eosin (H&E) staining or anti-CD3 immunohistochemical staining. (A) Microphotographs of 
stained sections were captured at 20× magnification. Representative examples of histological 
sections obtained on day 4 and 6 from mice transferred with GRflox and GRlck T cells are shown; 
scale bar: 200 µm. (B) The histological score was determined in H&E stainings and assessed by 
an established scoring system as described before. (C) Numbers of infiltrating T cells were 
determined using anti-CD3 immunohistochemical stainings and counted per mm2. N=5 for each 
group. Statistical analysis was done using unpaired Student’s t-test, **, p < 0.01; n.s., not 
significant; (Li et al., 2019). 
 
On day 4 after aGvHD induction, the villi in mice receiving GRflox and GRlck T cells were 
morphologically intact (Figure 19A); the histological score showed no significant 
differences between mice receiving GC-resistant T cells and those receiving GC-





compared to those with GRflox T cells at the full-blown first stage of the disease, which 
was supported by our histological scoring on day 6 revealing more excessive tissue 
damage in the former group of mice (Figure 19B). The disease was characterized by an 
increasing infiltration of CD3+ T cells from day 4 to 6 into the small intestine. However, 
GR-deficiency in allogeneic T cells did not impact the number of infiltrating CD3+ T 
cells in the inflamed small intestines; no differences were detected neither on day 4 nor 
day 6 (Figure 19C). 
Taken together, these data show that the exaggerated aGvHD is not caused by differential 
T cell infiltration into the small intestine but must rather be due to differences between 
instinct effector functions of the allogeneic T cells with GC-resistance and GC-
responsiveness. 
 
3.8 Serum protein levels of key inflammatory cytokines are elevated during the 
course of aGvHD in mice transferred with GC-resistant allogeneic T cells 
To investigate whether the tissue damage triggered by the infiltrating T cells in the 
inflamed small intestines correlated with the systemic levels of inflammatory cytokines, 
we collected blood from mice suffering from aGvHD via heart puncture on day 4, 5 or 6 
after transplantation. The systemic protein levels of IL-6, IFN-γ, and TNF-α were 
measured by ELISA. 
The production of these three cytokines in serum was already significantly increased in 
the early phase of the disease (day 4) in mice receiving GC-resistant T cells (GRlck) 
relative to those mice transferred with GC-responsive T cells (GRflox). This was also the 
case at the full-blown first stage of the disease (day 6). However, no significant 
differences in serum protein levels were observed on day 5 between mice receiving GRlck 
and GRflox T cells (Figure 20). Of note, the level of IFN-γ on day 5 was higher than on 







Figure 20. Serum protein levels of inflammatory cytokines during the course of aGvHD in 
mice. Murine aGvHD was induced by transferring allogeneic GC-resistant (GRlck) or GC-
responsive (GRflox) C57BL/6 T cells in combination with TCD bone marrow cells into lethally 
irradiated BALB/c mice via the tail vein. On day 4, 5, and 6, blood was collected by heart 
puncture from the recipient mice. Protein levels of IL-6 (A), IFN-γ (B), and TNF-α (C) were 
determined by ELISA. Sample size: N= 5/5/10 (day 4/5/6). Statistical analysis was performed 
with unpaired Student’s t-test, *, p < 0.05; **, p < 0.01; ***, p < 0.001; n.s., not significant; (Li et 
al., 2019). 
 
3.9 Expression analysis of the genes previously identified by RNA-sequencing 
Our RNA-sequencing data showed that more than 500 genes were differentially regulated 
in mice receiving GC-resistant T cells on day 6 after aGvHD induction (Figure 18C). 
Therefore, we selected 26 candidate genes from this list and reanalyzed their expression 
by high-throughput RT-qPCR. The selection criteria included gene alteration with a high 





gastrointestinal tract, and an involvement in inflammation. 
We found that the majority of analyzed genes were significantly altered at the full-blown 
first stage (day 6) of the disease, but only two genes, Ifng and Cxcl2, were already up-
regulated at the early stage (day 4). The transcriptional levels of genes encoding secreted 
proteins (Mt2a, Gzmb, Ifng, Orm2, and Cxcl2), molecules expressed on the cell surface 
(Cd274, Ccr2, Cxcr6, Il18r1, Tnfrsf9, Cldn4, and Il1r1), and intracellular enzymes 
(Hmox1, Itk, Ptges, and Rgs1) were all significantly up-regulated in mice transplanted 
with GC-resistant allogeneic T cells on day 6. Moreover, the expression level of two 
genes (S1prl and Sphk1) involved in sphingosine signaling was elevated in mice 
transplanted with GRlck T cells (Table 16). We also observed that three genes (Pfkfb3, 
Ldhd, and Slc2a3) associated with glycolysis were up-regulated in mice receiving GC-
resistant T cells. Furthermore, five genes (Aldh1b1, Acot1, Arg2, Otc, and Aoc1) related 
to metabolic pathways active in many non-hematopoietic cells, such as the urea cycle, 

















Table 16. Expression analysis of selected genes identified by RNA-seq during an early and 
late stage of the first phase of aGvHD in mice. Murine allogeneic HSCT was conducted by 
injecting allogeneic GC-resistant (GRlck) or GC-responsive (GRflox) T cells in combination with 
TCD bone marrow cells isolated from C57BL/6 mice into the tail vein of lethally irradiated 
BALB/c mice. RNA was isolated from small intestine biopsies on day 4 and 6 after disease 
induction. Complementary DNA was synthesized and used for Fluidigm® gene chip analysis. 
Expression alterations are depicted as fold-change of GRlck vs. GRflox (yellow for no changes, 
light green: ≤ 3-fold, dark green: > 3-fold, light blue: ≥ 0.3-fold, and dark blue: < 0.3-fold). 
N=4/5 (GRflox/GRlck, day 4), N=10/10 (GRflox/GRlck, day 6). Statistical analysis was done with 
unpaired Student’s t-test, *, p < 0.05; **, p < 0.01; ***, p < 0.001; n.s., not significant; (Li et al., 
2019). 
  GRlck vs. GRflox 
at day 4 
 GRlck vs. GRflox 













       
Metallothionein 2a Mt2a 1.1 n.s.  2.0 * 
Granzyme B Gzmb 1.3 n.s.  2.3 * 
IFN Ifng 5.2 *  2.7 ** 
Orosomucoid 2 Orm2 0.9 n.s.  5.0 ** 
CXCL2 Cxcl2 2.6 n.s.  6.3 * 
       
PD-L1  Cd274 1.6 n.s.  1.8 * 
CCR2 Ccr2 0.6 n.s.  2.2 * 
CXCR6 Cxcr6 1.1 n.s.  2.3 * 
IL-18R1 Il18r1 1.0 n.s.  2.4 * 
4-1BB Tnfrsf9 1.7 n.s.  2.8 ** 
Claudin 4 Cldn4 0.9 n.s.  2.8 ** 
IL-1R1 Il1r1 1.3 n.s.  5.3 *** 
       
Heme oxygenase 1 Hmox1 1.3 n.s.  1.9 * 
Inducible T-cell kinase Itk 0.7 n.s.  2.2 * 
Prostaglandin E synthase Ptges 1.3 n.s.  2.5 *** 
Regulator of gp signaling 1 Rgs1 0.9 n.s.  4.0 ** 
       
S1P receptor 1 S1pr1 1.2 n.s.  2.1 * 
Sphingosine kinase 1 Sphk1 1.0 n.s.  2.9 ** 
       
6-Phosphofructo-2-kinase Pfkfb3 1.5 n.s.  1.9 ** 
Lactate dehydrogenase D Ldhd 0.9 n.s.  2.1 * 
Slc2a3 / Glut3 Slc2a3 1.4 n.s.  2.4 ** 
       
Aldehyde dehydrogenase 1B1 Aldh1b1 1.1 n.s.  0.50 * 
Acyl-CoA thioesterase 1 Acot1 1.3 n.s.  0.42 * 
Arginase 2 Arg2 1.0 n.s.  0.26 * 
Ornithine transcarbamylase Otc 0.9 n.s.  0.24 ** 





3.10 Expression analysis of the genes identified by RNA-seq reveals cell-type 
specificity 
A number of genes identified by of RNA-seq had been further confirmed by high 
throughput gene expression analysis using Fluidigm® gene chip technique (Table 16). 
However, there was a limitation. Since we applied total RNA isolated from small 
intestine biopsies for the gene expression analysis, it could not distinguish between 
different types of cells that infiltrate or reside in the small intestine in the context of 
aGvHD, such as T cells, epithelial cells, and macrophages. However, it has been reported 
that these types of cells contribute differently to the progress of aGvHD (Koyama et al., 
2019; Perkey and Maillard, 2018). As a first approach to analyze the cell-type specificity 
of the identified genes, we purified splenic T cells from C57BL/6 mice, enriched 
peritoneal macrophages in BALB/c mice, and isolated epithelial cells from the small 
intestine of BALB/c mice. The specific expression of nine genes in these three cell-types 







Figure 21. Cell-type specificity analysis of selected genes identified by RAN-seq. Splenic T 
cells were magnetically purified from C57BL/6 mice. Thioglycolate was intraperitoneally 
injected into BALB/c mice, and peritoneal macrophages were enriched 4 days later. Intestinal 
epithelial cells (IECs) were isolated from BALB/c mice. RNA was subsequently isolated from 
these cell preparations, transcribed into cDNA, and used for RT-qPCR analysis. (A) Genes 
mainly expressed by T cells. (B) Genes predominantly expressed by IECs. (C) Genes 
preferentially expressed by macrophages. mRNA expression levels were determined using the 
∆∆Ct method and normalized to the house-keeping gene Hprt. N=3/3/5 (T cells/ IECs/ 
macrophages); (Li et al., 2019). 
 
Amongst the genes we assessed, three genes, Cxcr6, Ctla4, and Glut3 were mainly 
expressed by T cells and barely expressed by macrophages or IECs (Figure 21A). Otc, 
Arg2, and Aoc1 that were significantly down-regulated in mice transferred with GC-
resistant T cells were dominantly expressed by IECs and their expression in T cells and 
macrophages was nearly undetectable (Figure 21B). We also found that Il1r1, Dusp1, 
and Sphk1 were more strongly expressed by peritoneal macrophages with a relatively low 





genes that are differentially expressed under conditions when allogeneic T cells are GC-
resistant, show a highly cell type-specific expression pattern, therefore, highlighting the 
contributions of this cell-type specificity to mouse aGvHD. 
 
3.11 Administration of BMP-NPs alleviates aGvHD in mice with the beneficial GvL 
effect retained 
BMP-NPs are a type of functional inorganic-organic nanoparticles (IOH-NPs) used for 
targeted delivery of GCs to endocytic cells. They are composed of 
[ZrO]2+[(BMP)0.9(FMN)0.1]
2- (BMP: betamethasone phosphate; FMN: flavin 
mononucleotide). In previous experiments of our group, it was demonstrated that BMP-
NPs were preferentially taken up by macrophages but hardly by T cells both in vitro and 
in vivo (Kaiser et al., 2020a; Montes-Cobos et al., 2017). Importantly, APCs such as 
macrophages make an essential contribution to the development of aGvHD in mice 
(Shlomchik, 1999). Based on the discovery of the cell type-specificity of BMP-NPs, we 
hypothesized that treatment of aGvHD with BMP-NPs not only reduces the severity of 
the disease in mice, but may also preserve the beneficial GvL effects compared to free 
GCs with the GR ubiquitously expressed in all nucleated cells. 
To analyze the GvL effect, we induced a combined aGvHD/GvL mouse model. It has 
been previously reported that the Bcl1 lymphoma shows massive splenic involvement and 
expresses a monoclonal λ-type immunoglobulin that could serve as a convenient marker 
to track down Bcl1 lymphomagenesis (Warnke et al., 1979). Prior to standard aGvHD 
induction, 3,000 Bcl1 cells were injected into recipient BALB/c mice via the tail vein to 
induce lymphomagenesis. Mice were monitored daily for their aGvHD clinical score and 
either treated with PBS, free betamethasone (BMZ), EP-NPs 
([ZrO]2+[(HPO4)0.9(FMN)0.1]
2-), or BMP-NPs on day 3, 4, 5, 7, 9, and 12. FACS analysis 
of the percentage of λ-type immunoglobulin cells in peripheral blood was carried out 
starting from day 21. Mice were sacrificed for ethical reasons according to the assessment 







Figure 22. Survival rate and lymphomagenesis of mice treated with different GC 
formulations. Induction of aGvHD was performed by transferring 1 × 107 T cell-depleted (TCD) 
bone marrow cells and 2 × 106 splenic T cells isolated from C57BL/c mice into BALB/c mice via 
the tail vein. Adaptive Bcl1 lymphoma cell transfer was conducted by injecting 3,000 Bcl1 cells 
into the BALB/c mice 4 hours before the induction of aGvHD, and mice receiving Bcl1 cells only 
served as a control. Mice were treated with PBS, free betamethasone (BMZ), EP-NPs, or BMP-
NPs on day 3, 4, 5, 7, 9, and 12. The severity of aGvHD and GvL was assessed based clinical 
symptoms and the frequency of Bcl1 cells in the blood. Mice were sacrificed when severe 
manifestations of aGvHD were observed or the percentage of Bcl1 cells in peripheral blood 
surpassed 50%. Sample size: N=15/10/14/4/10 (Bcl1 only / PBS / BMZ / EP-NPs / BMP-NPs). (A) 
Survival rate of mice in the combined aGvHD/GvL model (BMT+Bcl1) treated with PBS, BMZ, 
EP-NPs, or BMP-NPs, or of mice only receiving Bcl1 cells. (B) Development of a lymphoma in 
mice based on the average frequency of Bcl1 cells in the blood is shown for the three 
experimental groups surviving pass day 10. The data were pooled from five independent 
experiments. Survival rate was analyzed with Log-rank Mantel-Cox test, and Bcl1 
lymphomagenesis was analyzed using Kruskal-Wallis test followed by Dunn’s Multiple 





Mice transferred with BMT and Bcl1 cells and either treated with PBS or EP-NPs were 
all sacrificed no later than on day 8 due to the severe aGvHD symptoms. Mice transferred 
only with Bcl1 cells were killed starting from day 22 and all sacrificed within the third 
week after the induction of the combined aGvHD/GvL mouse model. Besides, mice 
administered with BMZ or BMP-NPs were sacrificed due to aGvHD symptoms or the 
development of a Bcl1 lymphoma, and showed a better survival rate than those mice only 
receiving Bcl1 cells. Moreover, treatment with BMP-NPs could slightly better prolong the 
survival of mice compared to BMZ treatment, though not significantly (Figure 22A).  
In order to investigate the progress of the Bcl1 lymphoma, we detected the percentage of 
Bcl1 cells in the peripheral blood using FACS Igλ staining and analyzed 
lymphomagenesis in all mice combined as well as in individual animals (Figure 22B and 
23). Mice transferred with only Bcl1 cells demonstrated the occurrence of a lymphoma 
starting from day 21 after transplantation, and the percentage of Bcl1 cells in the 
peripheral blood rapidly increased thereafter, reaching the maximal amount of 50 percent. 
Relative to those mice receiving only Bcl1 cells, mice with aGvHD and treated with BMZ 
or BMP-NPs showed a trend to a delayed Bcl1 lymphoma development. Besides, the 
progress of the Bcl1 lymphoma was slower in mice treated with BMP-NPs compared to 
those administered with BMZ (Figure 22B).  
All 15 mice receiving only Bcl1 cells had over 50 percent of lymphoma cells in the blood 
until day 27. In the BMZ treatment group, 7 mice died of aGvHD, and 7 mice developed 
a lymphoma or remained healthy until day 40 when the experiment was terminated. 
Amongst the mice administered with BMP-NPs, 4 died of aGvHD and 6 developed a 
lymphoma or were healthy until day 40 (Figure 23). These data suggest that transfer of 
allogeneic T cells combined with GC treatment delays Bcl1 lymphomagenesis in mice 
significantly better when BMP-NPs are used instead of free BMZ, although in the end, 






Figure 23. Frequency of Bcl1 cells in the blood of individual mice in a combined 
aGvHD/GvL mouse model. Murine aGvHD was induced by transferring 1 × 107 T-cell-depleted 
(TCD) bone marrow cells and 2 × 106 splenic T cells isolated from C57BL/c mice into BALB/c 
mice via the tail vein. Mice were treated with BMZ or BMP-NPs on day 3, 4, 5, 7, 9, and 12. 
Adaptive transfer of a Bcl1 lymphoma was induced by injecting 3,000 Bcl1 cells into the BALB/c 
mice 4 hours before aGvHD induction, and mice receiving only Bcl1 cells served as a control. 
The expansion of Bcl1 cells in the peripheral blood was measured by FACS analysis based on Igλ 
staining. Sample size: N=15/14/10 (Bcl1 only / BMZ / BMP-NPs). The data refer to the same 





3.12 Cytolytic ability of CD8+ T cells after short-term treatment with BMP-NPs  
We found that the administration with BMP-NPs delayed the development of a Bcl1 
lymphoma in the combined aGvHD/GvL mouse model. Next, we aimed to assess the 
cytolytic ability of splenic cytotoxic lymphocytes (CTLs) in vivo after short-term 
treatment with BMP-NPs or BMZ. To achieve this goal, we induced aGvHD by 
transplanting magnetically purified allogeneic T cells in a combination with TCD bone 
marrow cells into BALB/c mice via the tail vein, and treated the mice with PBS, BMZ or 
BMP-NPs on day 3, 4, and 5 intraperitoneally. On day 6 after the aGvHD induction, 
splenic CD8+ cells were isolated from the recipient mice and tested for their cytolytic 
ability on target Bcl1 cell using a 
51chromium release assay. The lysis assay was carried 








Figure 24. Lytic ability of cytotoxic T lymphocytes (CTLs) against Bcl1 target cells after 
short-term treatment of aGvHD with BMP-NPs or BMZ. Splenic CD8+ T cells were 
magnetically isolated from mice suffering from aGvHD on day 6 after disease induction. Bcl1 
cells used as target cells were co-cultured in medium in the presence of effector CTLs, and the 
specific lysis was measured at different effector: target ratios by 51chromium release assay. (A) 
Specific lysis compared between mice treated with PBS or BMP-NPs, N=3/4 (PBS / BMP-NPs). 
(B) Specific lysis compared between mice treated with PBS or BMZ, N=3/6 (PBS / BMZ). (C) 
Specific lysis compared between mice treated with BMP-NPs or BMZ, N=6/6 (BMP-NPs / BMZ). 
Data are shown as mean ± SD. 
  
 
The cytolytic ability of splenic CTLs isolated from aGvHD mice on day 6 administrated 
with BMZ or BMP-NPs was decreased in comparison of those CTLs treated with PBS in 
vivo (Figure 24A and B). Furthermore, when mice were treated with the two different 
GCs in one trial, CTLs from BMP-NPs treated mice were slightly more efficient in 







4.1 GC-resistance of allogeneic donor T cells causes aggravated aGvHD in mice 
HSCT is a potentially curative and effective therapeutic approach to treat various 
hematological diseases. However, its broader use is limited by the frequent occurrence of 
GvHD, which is a major complication after allogeneic HSCT and causes high morbidity 
and mortality (Copelan, 2006; Deeg, 2007). Systemic GCs, such as methylprednisolone, 
are the most common first-line therapy for the treatment of aGvHD (Sung and Chao, 
2013), although a long-term or high-dose treatment with GCs is often accompanied by 
adverse effects including an increased risk of infection, aseptic necrosis, and osteopenia 
(Deeg, 2007). Moreover, it may occur that there is no response to GC treatment, which is 
termed “GC-resistant” or “steroid-refractory”. In the setting of aGvHD, approximately 60% 
of patients develop steroid-refractory GvHD and do not respond to this first-line therapy 
(Przepiorka et al., 2020). The mechanisms of steroid-resistance, however, are still poorly 
understood.  
4.1.1 GC-resistant aGvHD in mice 
In our experiments, we initially induced murine aGvHD by using GC-resistant (GRlck) 
allogeneic T cells in which the GR was genetically deleted in the entire T cell lineage. 
Transplantation of GC-resistant or GC-responsive T cells both resulted in aGvHD in 
recipient mice, but the disease was exaggerated in the former case. More specifically, 
mice transferred with GC-resistant allogeneic T cells showed more severe clinical 
symptoms than those receiving GC-responsive cells. In a previous report, only those mice 
transplanted with GC-responsive but not GC-resistant allogeneic T cells survived 
throughout the first phase of aGvHD and then succumbed to death in the second phase of 
the disease (Theiss-Suennemann et al., 2015). This finding highlights the importance of 
the effects of endogenous GCs on allogeneic donor T cells in the development and 
severity of aGvHD in mice. However, not only allogeneic donor T cells but also various 
types of APCs play an important role in the pathophysiology of aGvHD (Ferrara et al., 





more severe aGvHD relative to mice harboring GC-responsive myeloid cells in the full-
blown first phase of the disease, and it was found that the aggravated clinical symptoms 
observed in GRlysM mice were accompanied by a dramatic drop of body temperature 
(Baake et al., 2018). Overall, our results as well as earlier ones thus suggest that GC-
resistance of donor T cells and recipient myeloid cells both triggers a more severe 
aGvHD in mice, thus providing ideal models to study GC-resistant aGvHD. 
4.1.2 Phenotype of mice transferred with GRlck or GRflox allogeneic T cells 
The different disease course of mice transplanted with GC-resistant or GC-responsive 
allogeneic T cells could either be caused by intrinsic differences between both cell types 
or it could be due to their differential responsiveness to GCs. In the pathophysiology of 
aGvHD, activated donor allogeneic T cells migrate to the target organs after being primed 
by APCs, and this progress is mediated by various adhesion molecules and chemokine 
receptors expressed on the surface of T cells (Zeiser et al., 2016). T cell-depletion in the 
graft is an option to prevent aGvHD after HSCT, however, accompanied by higher rates 
of infection and relapse. Therefore, specific removal of alloreactive precursors contained 
in donor T cells would be a potent treatment of aGvHD (Li Pira et al., 2016), which also 
highlights the importance of the activation condition of donor T cells. Classically, T cells 
are divided into CD4 and CD8 subsets, which recognize MHC II and MHC I complexes 
expressed on APCs, respectively. Targeted deletion of CD4+ donor T cells is linked to 
altered production of inflammatory cytokines in mouse aGvHD (Ni et al., 2017), and 
suppression of CTL activity of CD8+ T cells appears crucial for endogenous GCs to 
control aGvHD (Theiss-Suennemann et al., 2015). Furthermore, FoxP3+ Treg cells have 
the ability to maintain peripheral tolerance in many inflammation-related disorders. For 
instance, it has been reported that donor-derived Treg cells were capable of suppressing 
lethal aGvHD after HSCT, and adaptive transfer of Treg cells has therefore emerged as a 
promising therapeutic approach to prevent or treat GvHD (Cohen et al., 2002; Hoffmann 
et al., 2002).  
Our flow cytometric data suggest that the frequencies of different subsets amongst GC-





adhesion molecules and chemokine receptors remained at a comparable level, indicating 
that GC-resistant and GC-responsive T cells possess an equal ability of cell migration. It 
has to be noted that GC-resistant CD8+ T cells were slightly more activated than GC-
responsive ones, which could at least to some extent contribute to the aggravation of the 
disease in this experimental group. Nevertheless, the majority of differences in aGvHD 
severity are most likely caused by GC-resistance of T cells contained in the transplant 
rather by their different composition. 
4.1.3 Systemic levels of inflammatory cytokines during aGvHD in mice 
Acute GvHD is characterized by donor allogeneic T cells attacking vital recipient organs. 
These target organs of aGvHD include skin, liver and GI tract (Ferrara et al., 2009). 
Patients with hematological malignancies are often treated with conditioning regimens 
aiming at the removal of tumor cells and creating suitable conditions for receiving 
transfused stem cells. However, these regimens, such as high-dose TBI, commonly cause 
tissue damage and particularly result in the loss of epithelial cell integrity of the GI 
system, which triggers the release of inflammatory cytokines (IFN-γ, IL-1, and TNF-α) 
(Perkey and Maillard, 2018). IFN-γ is a hallmark of inflammation and is involved in 
many autoimmune and metabolic diseases (Ivashkiv, 2018), but the role of IFN-γ in the 
context of aGvHD is debatable. It was reported that IFN-γ reduced the injury of epithelial 
GvHD target tissues and increased the desired GvL effect (Wang et al., 2009). TNF-α is 
highly present in aGvHD patients and specifically plays an important role in the GI 
manifestations of GvHD (Deeg, 2007). Moreover, the anti-TNF-α monoclonal antibody 
infliximab has been used to treat aGvHD. Similarly, administration of tocilizumab, a 
monoclonal antibody targeting IL-6 receptor, attenuated aGvHD in mice (Chen et al., 
2009). Also, a murine aGvHD induced in GRdim recipient mice, in which the dimerization 
of the GR is impaired (Reichardt et al., 1998), showed alleviated disease manifestations 
after the treatment with an anti-IL-6 monoclonal antibody (Baake et al., 2018). 
In this work, we found that systemic serum levels of IFN-γ and IL-6 were increased in 
mice transferred with GC-resistant T cells during the full-blown phase of mouse aGvHD. 





development of aGvHD in mice, even at the early stage of the disease, suggesting that the 
signs of inflammation were caused by the tissue damage in the initial phase after TBI. 
Besides, higher systemic serum levels of these two cytokines and IFN-γ were detectable 
in mice receiving GC-resistant T cells compared to ones transplanted with GC-responsive 
T cells at either the early or late full-blown phase of the disease, highlighting the 
contribution of endogenous GCs in controlling the initiation and rapid aggravation of 
mouse aGvHD by donor allogeneic T cells. Interestingly, the production of IFN-γ 
reached its highest level before the full-blown stage of aGvHD and was then lowered at 
the full-blown stage. Moreover, IFN-γ serum levels are in agreement with its gene 
expression pattern in the early and full-blown phases of the disease, characterized by 
increased mRNA levels in mice receiving GC-resistant T cells compared to those 
transplanted with GC-responsive T cells. Thus, our data further confirm the contribution 
of systemic inflammatory cytokines to the development of aGvHD and the GCs’ 
biological functions to suppress them at a systemic level in the context of this disease. 
4.1.4 Histological and immunohistochemical analyses of the small intestine of 
aGvHD mice  
In the effector phase of aGvHD, the target organs undergo severe damage, which is 
highlighted by massive infiltration of effector T cells (Zeiser and Blazar, 2017). In line 
with our clinical data, histological staining only showed significant difference in the full-
blown first phase between the inflamed small intestines of mice receiving GC-resistant 
and GC-responsive T cells, but not in the initiation phase of the disease. Concerning our 
gene expression data, which were obtained by analyzing total RNA from an entire section 
of the inflamed small intestine, it was necessary to test whether the alterations were 
caused by different numbers of infiltrating effector T cells or by cell-intrinsic differences 
in mRNA levels. Therefore, we carried out immunohistochemical stainings, which 
revealed similar numbers of infiltrating CD3+ T cells in the small intestine at different 
time points of the disease, indicating that the altered gene expression profile is a result of 






4.2 GC-resistance in allogeneic T cells alters the gene expression profile of mice 
suffering from aGvHD 
Patients who develop aGvHD are treated with systemic GCs, such as methylprednisolone, 
at a dose of 2 mg/kg, followed by a gradually reduced dose if they respond. For non-
responders, a higher dose of GCs is given in combination with immunosuppressants 
(Deeg, 2007). Those patients who are GC-resistant show poor clinical outcome with a 
low survival rate. An important question is, when second-line therapy should be initiated. 
Therefore, there is an urgent need for the development of biomarkers that would allow to 
predict GC-resistance and thus to timely start a second-line therapy. In a previous study, 
it has been proposed to use serum levels of suppressor of tumorigenicity-2 (ST2) and 
regenerating islet-derived protein 3 (REG3) to predict steroid-refractory aGvHD after one 
week of GC treatment, reflecting a better prognostic outcome than only relying on 
clinical criteria (Major-Monfried et al., 2018). Similarly, T-cell immunoglobulin mucin-3 
(TIM3) has been shown to be closely associated with severe aGvHD in patients and 
particularly linked to steroid-refractory GvHD (McDonald et al., 2017). In contrast to 
these serum biomarkers, up to now, there are only a few studies focusing on discovering 
genes that are correlated to GC-resistance in the treatment of aGvHD. In an experimental 
aGvHD mouse model, expression of inflammatory cytokines, chemokines, and adhesion 
molecules, as well as their receptors, was found to be down-regulated after prednisolone 
treatment (Bouazzaoui et al., 2011). However, the relevance of these results is limited by 
the small scale of investigated genes. In previous experiments of our group, it was found 
that the transfer of GC-resistant allogeneic T cells led to an alteration of gene expression 
in spleen, namely Ifng and cytotoxicity-related genes largely secreted by CD8+ T cells 
(Theiss-Suennemann et al., 2015). However, the number of the analyzed genes was also 
small and gene expression analysis was limited to a secondary lymphoid organ instead of 
any of the main target organs of aGvHD. It is against this background that we 
hypothesized that genes could potentially be identified that are suitable for the 
predication or targeted treatment of aGvHD, by using a high-throughput technique to 
analyze gene expression in the small intestine, one of the main target organs, in a setting 





4.2.1 Gene expression analysis of mice receiving GRlck T cells or harboring GRlysM 
myeloid cells 
We initially conducted a Fluidigm® gene chip assay to analyze the expression of genes 
already known to be involved in the pathophysiology of aGvHD. Based on literature, we 
categorized these genes into five groups. We found that the expression pattern of these 
genes was mostly altered due to the transplantation of GC-resistant allogeneic T cells in 
the full-blown first phase of the disease. Even though the recipient mice with GC-
resistant myeloid cells showed severe clinical aGvHD symptoms at this stage of the 
disease as well, the gene expression profile remained mostly unaffected in the GRlysM 
aGvHD mouse model. As a matter of fact, it is likely that the aggravated disease 
symptoms here are predominantly caused by the elevated release of systemic 
inflammatory cytokines, such as IL-6 and TNF-α (Baake et al., 2018). Resident 
macrophages in the lamina propria of the intestine are the most radio-resistant part of 
myeloid cells (Bosurgi et al., 2013) and therefore many GC-resistant myeloid cells still 
existed in our aGvHD mouse model. However, our data also show that donor-derived 
myeloid cells contained in graft migrated into the inflamed small intestine and thereby 
contributed to the composition of myeloid cells in this target organ. Hence, in the case of 
the GRlysM aGvHD mouse model, it is likely that donor-derived GC-responsive myeloid 
cells infiltrate into the inflamed small intestine, thereby concealing the effects of GC-
resistance of recipient-derived myeloid cells on gene expression.  
Our data indicate that genes in the category “cytokines & chemokines” were strongly 
affected by GC-resistance of allogeneic T cells. It is not surprising that we observed that 
Il1b and Il6 were up-regulated in mice transplanted with GC-resistant allogeneic T cells 
due to their inflammatory functions in the disease, as well as that Il2 and Il12 were 
increased due to their critical role in T cell proliferation and differentiation. It has been 
reported that GM-CSF secreted by Bhlhe40+ donor T cells promoted GvHD by recruiting 
and activating donor dendritic cells in the GI tract (Piper et al., 2020). In agreement, the 
expression of Csf2 was increased in mice receiving GC-resistant T cells. Besides, donor 
T cells become alloactivated in the context of aGvHD; it is thus reasonable that 





developing more severe disease. Furthermore, it is known that GCs inhibit the expression 
of the majority of cytokines (Cain and Cidlowski, 2017). In addition, various chemokines 
exert their functions by regulating the migration of effector T cells into target organs of 
GvHD (Zeiser et al., 2016). For instance, CXCL10 which is induced by IFN-γ becomes 
strongly expressed after conditioning and is consistently expressed during the 
development of GvHD (Mapara et al., 2006). In our study, the selected genes encoding 
chemokines were all up-regulated in mice transferred with GC-resistant allogeneic T cells 
compared to mice transplanted with GC-responsive allogeneic T cells, reflecting the 
impact of GCs on modulating chemotaxis of immune cells towards the small intestine, a 
main target organ of aGvHD. 
In our study, genes related to leukocyte surface antigens were also analyzed. Our data 
reveal that GC-resistance resulted in a changed expression of genes associated with T 
cells (Cd28, Fasl), macrophages (Cd14, Chil3), and NK cells (Klrk1), demonstrating that 
different types of immune cells were affected in the GI tract in GC-resistant aGvHD. In 
the case of intracellular proteins, myeloid cell-specific genes (Ptgs2, Arg1) were 
presumably indirectly affected by GC-resistance in T cells, which is probably due to the 
severe inflammatory response in mice receiving GC-resistant T cells. 
Reprogramming of T-cell metabolism has been widely investigated in recent years. A 
series of metabolic changes occur during the processes of T-cell activation and 
differentiation, which are required to meet a rapidly increased need for biosynthesis of 
many metabolites as well as ATP production (Wahl et al., 2012). It has been reported that 
alloreactive donor T cells present in GvHD showed increased aerobic glycolysis and 
oxidative phosphorylation (Gatza et al., 2011). These metabolic changes occurring during 
GvHD can be fueled by glycolysis and glutamine metabolism. c-Myc is capable of 
directing the expression of the majority of genes involved in these two metabolic 
processes (MacIver et al., 2013), and low activity of c-Myc is linked to low aerobic 
glycolysis in murine GvHD  (Kato et al., 2010). However, in our aGvHD mouse model, 
the expression level of Myc was unaffected. The two genes Glut1 and Hk2, which are 
important in the context of aerobic glycolysis, were significantly up-regulated in the 





Slc7a5 and Slc1a5 was unaltered in our aGvHD mouse model. EERα plays an important 
role in regulating mitochondrial metabolic pathways and in modulating the expressions of 
genes associated with mitochondrial energy, such as Ppargcla and Cpt1a (Giguère, 2008). 
Nevertheless, the expression of these two genes was unaffected by GC-resistance in T 
cells. Besides c-Myc, HIF-1α also boosts glycolysis during activation of immune cells, 
which can be achieved by activating lactate dehydrogenase (LDH) while inhibiting 
pyruvate dehydrogenase (PDH) (Kim et al., 2006). Such a metabolic function of HIF-1α 
was further confirmed on the gene expression level by our data with Hif1a being up-
regulated and Pdha1 being unchanged. 
4.2.2 Expression analysis by RNA-sequencing  
We additionally performed an unbiased RNA-sequencing analysis and found 
approximately 500 genes to be differentially expressed in the inflamed small intestine of 
mice receiving GC-resistant allogeneic T cells in comparison to mice transplanted with 
GC-responsive allogeneic T cells. Amongst the large number of newly identified genes, 
we reanalyzed the expression of 26 candidates in either the early or full-blown phase of 
the disease by high-throughput RT-qPCR. Importantly, our data revealed that the altered 
gene expression profile was only observed in the full-blown phase of the disease. 
Amongst the 26 genes, those related to key effector functions of T cells showed a 
significantly increased expression due to the GC-resistance of allogeneic T cells, such as 
Ifng and Gzmb. Metallothioneins (MTs) are a type of stress-sensors that are linked to 
immune responses. It has been reported for a DSS-induced colitis mouse model, that MT-
deficiency in mice resulted in a decreased severity of colitis, and that administration of an 
Mt2 monoclonal antibody improved clinical outcome (Devisscher et al., 2014). In our 
study, Mt2a was transcriptionally increased because of the GC-resistance in T cells, 
suggesting a potential role of this protein in the context of aGvHD as well, thus 
recommending it as a potential therapeutic target in this disease. The protein encoded by 
Orm2 belongs to a family of acute-phase proteins responding to cytokines (Lee et al., 
2010), and this gene was also up-regulated in our GC-resistant aGvHD model. Not 





increased in mice transferred with GC-resistant T cells, being in line with the previous 
observation that a majority of chemokine-related genes showed a similar trend in our 
gene expression analysis by high-throughput RT-qPCR. 
Membrane proteins are a promising drug target due to their accessibility by monoclonal 
antibodies and small molecular compounds. It has been shown that transplantation of PD-
L1-deficient T cells alleviated aGvHD in mice (Saha et al., 2015). In agreement with this 
finding, we observed an increase of Cd274 at the transcriptional level in mice receiving 
GC-resistant allogeneic T cells. Additionally, GC-resistance in transferred T cells also 
resulted in an upregulation of several genes associated with T cell function (Il18r1, Il1r1, 
Tnfrsf9) as well as migration (Cxcr6). IL-18 belongs to the IL-1 cytokine family and can 
be produced by non-hematopoietic cells; its receptor IL-18R1 is highly expressed by 
intestinal CD4+ T cells, thus contributing to chronic inflammatory diseases (Harrison et 
al., 2015). 4-1BB encoded by Tnfrsf9 can lead to the expansion of CD8+ T cells and 
enhance their cytotoxic ability (Shuford et al., 1997). Moreover, 4-1BB monoclonal 
antibodies have been developed and tested in a clinical trial (Ascierto et al., 2010). In 
another study, it was shown that CXCR6 was highly expressed by liver-infiltrating CD8+ 
T cells and was responsible for GvHD-induced liver inflammation because of its 
recruitment ability (Sato et al., 2005). Besides genes mainly expressed by immune cells, 
Cldn4 was up-regulated in mice transplanted with GC-resistant T cells. This gene 
encodes a protein belonging to the claudin family, which is the main component of the 
tight junctions. Additionally, claudins are tightly associated with many intestinal 
disorders that cause weight loss and diarrhea (Barmeyer et al., 2015). Overall, our data 
indicate that genes expressed by various types of cells can be potentially targeted in 
aGvHD, used as a biomarker for its treatment, or even assist with the prognosis of GC-
resistant disease, suggesting the massive involvement of different cells in the inflamed 
small intestine. 
Our gene expression data also show that intracellular proteins were involved in mouse 
aGvHD. However, intracellular proteins are not as convenient as cell membrane antigens 
for therapeutic targeting, since drug delivery would demand translocation into the 





and hypoxia (Yamamoto et al., 2019), and elevated expression of HO-1 alleviated 
aGvHD in both humans and mice (Yu et al., 2016). Itk plays an essential role in CD8+ T 
cells, and inhibition of ITK was found to have a curative effect on GvHD (Schutt et al., 
2015). Rgs1 encodes the regulator of G protein, which is the only gene without enzymatic 
activity in the group of intracellular proteins in our analysis. Previously, it was reported 
that this gene was involved in guiding T cell trafficking into the gut (Gibbons et al., 
2011), indicating that the high expression of Rgs1 in our model might contribute to 
further intestinal damage by mediating the infiltration of effector T cells into this target 
organ. S1pr1 and Sphk1, two genes associated with S1P signaling, were upregulated in 
our aGvHD mouse model. In an earlier study, treatment with a specific agonist of S1P 
receptors was capable of controlling the development of aGvHD by reducing the number 
of macrophages in a target organ of the disease (Cheng et al., 2015). Moreover, it has 
been shown that S1P1 plays an essential role in modulating the egress of matured T cells 
from the thymus to peripheral tissues (Allende et al., 2004). Thus, our gene expression 
data combined with these findings could indicate the upregulation of S1pr1 and Sphk1 
contributes to the enhanced migration of effector T cells into the inflamed small intestine 
in our GC-resistant aGvHD mouse model. 
In our previous gene expression data, we had discovered that the expression level of three 
genes (Slc2a1, Hif1a, Hk2) involved in T-cell metabolism, especially glycolysis, were 
significantly increased in mice receiving GC-resistant T cell. Amongst the 26 genes that 
were identified by RNA-seq analysis, three other genes closely associated with T-cell 
metabolic reprogramming, namely Pfkfb3, Ldhd and Slc2a3, were also found to be up-
regulated due to the GC-resistance of the transplanted T cells. In the context of GvHD, 
alloreactive T cells undergo various metabolic changes to promote the development of 
the disease and to contribute to an aggressive immune response (Wahl et al., 2012). 
Previous findings suggest that increased glycolysis was required for alloactivated T cells 
to exert their functions in the initiation and development of aGvHD, and that targeting of 
the key glycolytic enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 
(PFKFB3) attenuated the severity of GvHD in mice (Nguyen et al., 2016). The increased 





the activation of Th17 cells (Dang et al., 2011). Furthermore, lactate dehydrogenase D 
encoded by Ldhd metabolizes D-lactate produced by microorganisms in gut (Ewaschuk et 
al., 2005). Therefore, we suppose that D-lactate could be utilized as a conditional energy 
supply for effector function and alloactivation of T cells in the inflamed small intestine. 
In line with the upregulation of Glut1 in our previous analysis, the expression of another 
glucose transporter Glut3 was also increased, which further demonstrates the critical role 
of glucose as nutrient fueling glycolysis in the development of aGvHD in mice. Finally, 
our data show that three genes (Otc, Arg2, Aoc1) involved in the urea cycle and fatty acid 
along with amino acid metabolism were downregulated in mice transferred with GC-
resistant T cells. Since these genes are predominately expressed in intestinal epithelial 
cells, their reduced mRNA levels could reflect the destruction of this cell type during the 
development of murine aGvHD. Overall, our data show that GC-resistance of allogeneic 
T cells in mouse aGvHD alters the expression profile of genes related to glycolysis, 
especially glucose uptake and other energy sources, indicating that T-cell metabolism 
plays, at least partially, a role in the therapeutic action of GCs. 
In conclusion, our data provide a general overview of genes being differentially 
expressed in the context of endogenous GC-resistance in mouse aGvHD, suggesting that 
these genes could be considered as potential biomarkers to predict GC-refractory GvHD 
or even to be targeted as a therapeutic approach to treat aGvHD. However, the technique 
we used for gene expression analysis has its limitations. Firstly, we only analyzed gene 
expression in one target organ, namely the small intestine. Damage in this target organ 
mainly contributes to the high morbidity and mortality of aGvHD, but inflammation or 
damage in liver is also a major characteristic of this disease. Therefore, further gene 
analyses of the inflamed liver are required and a combination of gene expression data in 
both target organs might more precisely provide information about genes that can serve 
as therapeutic targets or biomarkers for the prediction of aGvHD. Secondly, since many 
types of cells exist in inflamed small intestine, particularly in the lamina propria, we have 
not yet confirmed whether the differentially expressed genes are exclusively expressed by 
T cells or other cell types, such as intestinal epithelial cells or macrophages. Up to now, 





RNA-seq. Thirdly, it is uncertain whether the alterations in gene expression directly 
contribute to the severe phenotype of aGvHD or whether they are indirectly triggered by 
inflammation caused by aGvHD, thus only being the result of compensatory mechanisms. 
To solve this issue, monoclonal antibodies or knock-out mice could be used for specific 
targeting. To eventually assess the cell-type specificity for each of the identified genes, 
much more laboratory work is surely needed. 
 
4.3 Glucocorticoids encapsulated in IOH-NPs sustains GvL activity 
GvHD is a disease that frequently develops after subjecting patients to allo-HSCT. In this 
setting, donor allogeneic T cells are the main contributors that lead to a high non-relapse 
fatality rate. To ensure suitable conditions in patients that will receive donor stem cells, 
they commonly undergo myeloablative conditionings (Singh and McGuirk, 2016). One 
disadvantage of these regimens is the limitation that they cannot be used in older patients 
as shown in clinical trials. Therefore, many non-myeloablative approaches have been 
developed (Gyurkocza and Sandmaier, 2014). Besides the various conditionings for the 
eradication of malignant cells, also the existence of the beneficial activity of allogeneic T 
cells, namely the GvL effects, has been noticed, and numerous studies have aimed at 
exploiting this beneficial effect to augment GvL activity while suppressing GvHD 
(Rezvani and Storb, 2008).  
GCs being the most widely applied first-line therapy to treat GvHD compromise GvL 
activity. Hence, the improvement of using GCs to treat GvHD with the GvL effect being 
preserved is an urgent need. Since GCs are capable of passively diffusing through the cell 
membrane with equal ability, their application results in an unspecific distribution in the 
human body. One possible approach to solve this problem is to modify drug delivery of 
GCs in order to change their uptake efficacy in different tissues or cell types. Henceforth, 
many drug delivery systems have been developed, and GCs delivered with PEGylated 
liposomes, polymeric micelles, and as polymer-drug conjugates were shown to have 





as rheumatoid arthritis and ulcerative colitis (Lühder and Reichardt, 2017). In contrast, 
little is known about the tailored drug delivery in the context of aGvHD. In our study, we 
used a nano-formulation of GCs (BMP-NPs), in which they are encapsulated in 
inorganic-organic nanoparticles. Previous data revealed that this nano-formulation of 
GCs was preferentially taken up by macrophages and had a beneficial impact in the 
treatment of a mouse model of multiple sclerosis (Montes-Cobos et al., 2017). Moreover, 
IP injection of BMP-NPs was found to lead to the accumulation of the drug in abdominal 
organs including the small intestine (Kaiser et al., 2020a). Besides, due to the ELVIS 
mechanism, these nanosized drugs should be preferentially enriched in inflamed tissues 
(Kopeček, 2013). Our group found that treatment with BMP-NPs in a mouse model of 
aGvHD reduced the severity of this disease, characterized by alleviated clinical 
symptoms, less immune cell infiltration and reduced levels of inflammation-related genes 
expressed locally in small intestine compared to the control group. In this respect, they 
showed similar therapeutic potency as free GCs (Kaiser et al., 2020b). Based on these 
findings, we further hypothesized that treatment of mouse aGvHD with BMP-NPs could 
additionally preserve the GvL activity of GCs. To address this issue, we used a combined 
aGvHD/GvL mouse model with Bcl1 cells adaptively transferred into recipient mice. 
Our data revealed that mice receiving either of the vehicles PBS and EP-NP died from 
severe aGvHD, which is consistent with our previous clinical score data. Mice 
transplanted only with Bcl1 cells developed a lymphoma from day 22 to 27 after 
induction. In contrast, treatment with the GC formulations BMZ and BMP-NPs both 
significantly extended survival. Of note, in this combined aGvHD/GvL model, the 
survival curve was comparable to that observed in our aGvHD mouse model related to 
the identical treatments (Kaiser et al., 2020b). We monitored the development of the 
adaptive Bcl1 lymphoma by tracking the abundance of lymphoma cells in peripheral 
blood. Our results indicate that treatment with BMP-NPs delayed lymphomagenesis of 
Bcl1, thus, at least partially maintaining GvL activity of the allogeneic T cells. However, 
it is noteworthy that the overall survival rates after administrations of BMZ and BMP-
NPs were similar, which might be explained by the presence of severe aGvHD during the 





relatively more severe aGvHD in our specific mouse model, causing difficulty in 
separating non-relapse rate from the overall survival rate. Moreover, the occurrence of 
lymphomagenesis was mainly unchanged, though the GvL activity was partially retained 
by the BMP-NPs treatment.  
Treatment with GCs compromises the cytotoxic ability of T cells that is required to 
eliminate residual malignant cells. We hypothesized that the nanosized formulation of 
GCs does not compromise the cytolytic ability of CD8+ T cells in the context of mouse 
aGvHD as it is the case for the free drug. To test this hypothesis, we induced aGvHD in 
mice and treated them with free GCs or BMP-NPs for a short time. CD8+ T cells were 
purified from mouse spleen at the full-blown first phase of the disease and further used 
for a 51chromium release assay. Our data show that the treatment with BMZ or BMP-NPs 
both reduced the cytolytic ability of CD8+ T cells compared to those isolated from mice 
treated with PBS. Furthermore, at a relatively low ratio of effector to target cells, the two 
formulations of GCs had a comparable impact on cytolytic ability. In contrast, it is 
reasonable to reckon that CD8+ T cells treated with BMP-NPs have stronger cytotoxicity 
than the cells treated with free GCs in the setting of a higher ratio of effector to target 
cells. Unfortunately, analysis at a high ratio was limited by the number of CD8+ T cells 
that could be isolated from spleen in our experiments. Since the cells were purified at the 
first full-blown phase of the disease, a large number of effector cells migrate from 
secondary lymphoid organs into the target organs, such as small intestine or liver in the 
context of aGvHD. Thus, we suppose that fewer CD8+ T cells remain in spleen at the 
full-blown first phase of the disease, which was also in line with our gene expression 
analysis, showing a majority of chemokines and genes involved in cell migration were 
up-regulated. Therefore, a further study might focus on investigating the cytolytic ability 
of cells in the target organs, or testing the cytotoxicity of CD8+ T cells after being treated 
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